{\rtf1\ansi\ansicpg936\cocoartf2638
\cocoatextscaling0\cocoaplatform0{\fonttbl\f0\fswiss\fcharset0 Helvetica;}
{\colortbl;\red255\green255\blue255;}
{\*\expandedcolortbl;;}
\paperw11900\paperh16840\margl1440\margr1440\vieww11520\viewh8400\viewkind0
\pard\tx566\tx1133\tx1700\tx2267\tx2834\tx3401\tx3968\tx4535\tx5102\tx5669\tx6236\tx6803\pardirnatural\partightenfactor0

\f0\fs24 \cf0 \{\\rtf1\\ansi\\ansicpg936\\cocoartf2638\
\\cocoatextscaling0\\cocoaplatform0\{\\fonttbl\\f0\\fswiss\\fcharset0 Helvetica;\}\
\{\\colortbl;\\red255\\green255\\blue255;\}\
\{\\*\\expandedcolortbl;;\}\
\\paperw11900\\paperh16840\\margl1440\\margr1440\\vieww30040\\viewh16520\\viewkind0\
\\pard\\tx566\\tx1133\\tx1700\\tx2267\\tx2834\\tx3401\\tx3968\\tx4535\\tx5102\\tx5669\\tx6236\\tx6803\\pardirnatural\\partightenfactor0\
\
\\f0\\fs24 \\cf0 \\\
<TYPE>10-K\\\
<SEQUENCE>1\\\
<FILENAME>a2167223z10-k.htm\\\
<DESCRIPTION>10-K\\\
<TEXT>\\\
<HTML>\\\
<HEAD>\\\
</HEAD>\\\
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>\\\
<BR>\\\
<FONT SIZE=3 ><A HREF="#06CHI1168_1">QuickLinks</A></FONT>\\\
<font size=3> -- Click here to rapidly navigate through this document</font>\\\
<!-- TOC_END -->\\\
\\\
\\\
<P><FONT SIZE=2>\\\
<hr noshade width=100% align=left size=4>\\\
<hr noshade width=100% align=left size=1> </FONT></P>\\\
\\\
<P ALIGN="CENTER"><FONT SIZE=4><B> UNITED STATES<BR>\\\
SECURITIES AND EXCHANGE COMMISSION<BR>  </B></FONT><FONT SIZE=2><B>WASHINGTON, D. C. 20549  </B></FONT></P>\\\
\\\
<HR NOSHADE ALIGN="CENTER" WIDTH="120">\\\
<P ALIGN="CENTER"><FONT SIZE=4><B>FORM 10-K  </B></FONT></P>\\\
\\\
<P><FONT SIZE=2><B> (MARK ONE)  </B></FONT></P>\\\
\\\
<!-- User-specified TAGGED TABLE -->\\\
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>\\\
<TR VALIGN="TOP">\\\
<TD WIDTH="4%"><BR><FONT SIZE=2><FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="93%"><BR><FONT SIZE=2><B>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></TD>\\\
</TR>\\\
<TR VALIGN="TOP">\\\
<TD COLSPAN=3 ALIGN="CENTER"><FONT SIZE=2><B><BR>\\\
OR</B></FONT></TD>\\\
</TR>\\\
<TR VALIGN="TOP">\\\
<TD WIDTH="4%"><BR><FONT SIZE=2><FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="93%"><BR><FONT SIZE=2><B>TRANSITION REPORT PURSUANT TO SECTION&nbsp;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></TD>\\\
</TR>\\\
</TABLE>\\\
<!-- end of user-specified TAGGED TABLE -->\\\
\\\
<HR NOSHADE ALIGN="CENTER" WIDTH="120">\\\
\\\
<!-- User-specified TAGGED TABLE -->\\\
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>\\\
<TR VALIGN="BOTTOM">\\\
<TD WIDTH="50%"><FONT SIZE=2><B>For the fiscal year ended December&nbsp;31, 2005</B></FONT></TD>\\\
<TD WIDTH="50%" ALIGN="RIGHT" VALIGN="TOP"><FONT SIZE=2><B>Commission file number 1-2189</B></FONT></TD>\\\
</TR>\\\
</TABLE>\\\
<!-- end of user-specified TAGGED TABLE -->\\\
\\\
<!-- User-specified TAGGED TABLE -->\\\
<TABLE WIDTH="90%" BORDER=0 CELLSPACING=0 CELLPADDING=0>\\\
<TR VALIGN="TOP">\\\
<TD WIDTH="38%" ALIGN="CENTER"><BR><FONT SIZE=2><B>\\\
<IMG SRC="g398140.jpg" ALT="LOGO" WIDTH="36" HEIGHT="32">\\\
 </B></FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="59%"><BR><FONT SIZE=5><B>Abbott Laboratories</B></FONT></TD>\\\
</TR>\\\
</TABLE>\\\
<!-- end of user-specified TAGGED TABLE -->\\\
\\\
<!-- User-specified TAGGED TABLE -->\\\
<DIV ALIGN="CENTER"><TABLE WIDTH="90%" BORDER=0 CELLSPACING=0 CELLPADDING=0>\\\
<TR VALIGN="TOP">\\\
<TD WIDTH="39%" ALIGN="CENTER"><BR><FONT SIZE=2><B> An Illinois Corporation</B></FONT></TD>\\\
<TD WIDTH="19%"><FONT SIZE=2><B><BR>&nbsp;</B></FONT></TD>\\\
<TD WIDTH="42%" ALIGN="CENTER"><FONT SIZE=2><B><BR>\\\
36-0698440</B></FONT></TD>\\\
</TR>\\\
<TR VALIGN="TOP">\\\
<TD WIDTH="39%" ALIGN="CENTER"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="19%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="42%" ALIGN="CENTER"><FONT SIZE=2>(I.R.S. employer identification number)</FONT></TD>\\\
</TR>\\\
<TR VALIGN="TOP">\\\
<TD WIDTH="39%" ALIGN="CENTER"><BR><FONT SIZE=2><B>100 Abbott Park Road</B></FONT></TD>\\\
<TD WIDTH="19%"><FONT SIZE=2><B><BR>&nbsp;</B></FONT></TD>\\\
<TD WIDTH="42%" ALIGN="CENTER"><FONT SIZE=2><B><BR>\\\
(847) 937-6100</B></FONT></TD>\\\
</TR>\\\
<TR VALIGN="BOTTOM">\\\
<TD WIDTH="39%" ALIGN="CENTER"><FONT SIZE=2><B>Abbott Park, Illinois 60064-6400</B></FONT></TD>\\\
<TD WIDTH="19%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="42%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=2>(telephone number)</FONT></TD>\\\
</TR>\\\
</TABLE></DIV>\\\
<!-- end of user-specified TAGGED TABLE -->\\\
\\\
<P ALIGN="CENTER"><FONT SIZE=2><B>Securities Registered Pursuant to Section&nbsp;12(b)&nbsp;of the Act:  </B></FONT></P>\\\
\\\
<!-- User-specified TAGGED TABLE -->\\\
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>\\\
<TR VALIGN="TOP">\\\
<TD COLSPAN=3><BR><HR NOSHADE></TD>\\\
</TR>\\\
<TR VALIGN="BOTTOM">\\\
<TH WIDTH="49%" ALIGN="CENTER"><FONT SIZE=1><B>Title of Each Class</B></FONT><BR></TH>\\\
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH WIDTH="49%" ALIGN="CENTER"><FONT SIZE=1><B>Name of Each Exchange<BR>\\\
on Which Registered</B></FONT><BR></TH>\\\
</TR>\\\
<TR VALIGN="TOP">\\\
<TD COLSPAN=3><HR NOSHADE></TD>\\\
</TR>\\\
<TR VALIGN="TOP">\\\
<TD WIDTH="49%"><FONT SIZE=2>Common Shares, Without Par Value<BR>\\\
(including Preferred Stock Purchase Rights)</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="49%"><FONT SIZE=2>New York Stock Exchange<BR>\\\
Chicago Stock Exchange<BR>\\\
Pacific Exchange</FONT></TD>\\\
</TR>\\\
<TR VALIGN="TOP">\\\
<TD COLSPAN=3><HR NOSHADE></TD>\\\
</TR>\\\
</TABLE>\\\
<!-- end of user-specified TAGGED TABLE -->\\\
\\\
\\\
<P><FONT SIZE=2><B>Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&nbsp;405 of the Securities Act.  </B></FONT></P>\\\
\\\
<P ALIGN="CENTER"><FONT SIZE=2><B> Yes<U>&nbsp;X&nbsp;</U>&nbsp;&nbsp;&nbsp;&nbsp;No<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>  </B></FONT></P>\\\
\\\
<P><FONT SIZE=2><B>Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d)&nbsp;of the Act.  </B></FONT></P>\\\
\\\
<P ALIGN="CENTER"><FONT SIZE=2><B> Yes<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;&nbsp;&nbsp;&nbsp;No<U>&nbsp;X&nbsp;</U>  </B></FONT></P>\\\
\\\
<P><FONT SIZE=2><B>Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section 13 or 15(d)&nbsp;of the Securities\\\
Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for\\\
the past 90 days.  </B></FONT></P>\\\
\\\
<P ALIGN="CENTER"><FONT SIZE=2><B> Yes<U>&nbsp;X&nbsp;</U>&nbsp;&nbsp;&nbsp;&nbsp;No<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>  </B></FONT></P>\\\
\\\
<P><FONT SIZE=2><B>Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to\\\
the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this\\\
Form&nbsp;10-K.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[X]</B></FONT></P>\\\
\\\
<P><FONT SIZE=2><B>Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of "accelerated filer and large\\\
accelerated filer" in Rule&nbsp;12b-2 of the Exchange Act.  </B></FONT></P>\\\
\\\
<P ALIGN="CENTER"><FONT SIZE=2><B>Large Accelerated Filer<U>&nbsp;X&nbsp;</U>&nbsp;&nbsp;&nbsp;&nbsp;Accelerated\\\
Filer<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;&nbsp;&nbsp;&nbsp;Non-accelerated Filer<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;&nbsp;&nbsp;&nbsp; </B></FONT></P>\\\
\\\
\\\
<P><FONT SIZE=2><B>Indicate by check mark whether the registrant is a shell company (as defined in Rule&nbsp;12b-2 of the Exchange Act).  </B></FONT></P>\\\
\\\
<P ALIGN="CENTER"><FONT SIZE=2><B> Yes<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;&nbsp;&nbsp;&nbsp;No<U>&nbsp;X&nbsp;</U>  </B></FONT></P>\\\
\\\
<P><FONT SIZE=2><B>The aggregate market value of the 1,487,731,767 shares of voting stock held by nonaffiliates of the registrant, computed by reference to the closing price\\\
as reported on the New York Stock Exchange, as of the last business day of Abbott Laboratories' most recently completed second fiscal quarter (June&nbsp;30, 2005), was approximately $72,913,733,900.\\\
Abbott has no non-voting common equity.  </B></FONT></P>\\\
\\\
<P><FONT SIZE=2><B>Number of common shares outstanding as of January&nbsp;31, 2006: 1,538,625,812  </B></FONT></P>\\\
\\\
<P ALIGN="CENTER"><FONT SIZE=2><B> <A NAME="ba1168_documents_incorporated_by_reference"> </A>\\\
<A NAME="toc_ba1168_1"> </A>\\\
<BR>  DOCUMENTS INCORPORATED BY REFERENCE    <BR>    </B></FONT></P>\\\
\\\
<P><FONT SIZE=2><B>Portions of the 2006 Abbott Laboratories Proxy Statement are incorporated by reference into Part III. The Proxy Statement will be filed on or about March 21,\\\
2006.</B></FONT></P>\\\
\\\
<P><FONT SIZE=2><hr\\\
noshade width=100% align=left size=1>\\\
<hr noshade width=100% align=left size=4> </FONT></P>\\\
\\\
<HR NOSHADE>\\\
<P style='page-break-before:always'></p>\\\
<!-- ZEQ.=1,SEQ=1,EFW="2167223",CP="ABBOTT LABORATORIES",DN="1",CHK=929362,FOLIO='blank',FILE='DISK132:[06CHI8.06CHI1168]BA1168A.;19',USER='EYOUNG',CD='16-FEB-2006;10:16' -->\\\
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->\\\
<P ALIGN="CENTER"><FONT SIZE=2><A\\\
NAME="page_de1168_1_1"> </A> </FONT></P>\\\
\\\
<!-- TOC_END -->\\\
<P ALIGN="CENTER"><FONT SIZE=2><A\\\
NAME="de1168_part_i"> </A>\\\
<A NAME="toc_de1168_1"> </A>\\\
<BR></FONT><FONT SIZE=2><B>PART I    <BR>    </B></FONT></P>\\\
\\\
\\\
<P><FONT SIZE=2><A\\\
NAME="di1168_item_1a._risk_factors"> </A>\\\
<A NAME="toc_di1168_3"> </A>\\\
<BR></FONT><FONT SIZE=2><B>ITEM 1A.&nbsp;&nbsp;&nbsp;&nbsp;RISK FACTORS    <BR>    </B></FONT></P>\\\
\\\
<P><FONT SIZE=2><B>Abbott may acquire other businesses, license rights to technologies or products, form alliances, or dispose of or spin-off businesses, which could cause it to incur\\\
significant expenses and could negatively affect profitability.</B></FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Abbott\\\
may pursue acquisitions of complementary businesses, technology licensing arrangements, and strategic alliances to expand its product offerings and geographic presence as part of\\\
its business strategy. Abbott may not complete these transactions in a timely manner, on a cost-effective basis, or at all, and may not realize the expected benefits of any acquisition,\\\
license arrangement, or strategic alliance. Other companies may compete with Abbott for these strategic opportunities. Further, even if Abbott is successful in making the acquisition, the products and\\\
technologies that are acquired may not be successful or may require significantly greater resources and investments than originally anticipated. Abbott may not be able to integrate acquisitions\\\
successfully into its existing business and could incur or assume significant debt and unknown or contingent liabilities. Abbott could also experience negative effects on its reported results of\\\
operations from acquisition-related charges, amortization of expenses related to intangibles and charges for impairment of long-term assets. These effects, individually or in combination,\\\
could cause a deterioration of Abbott's credit rating and result in increased borrowing costs and interest expense. Abbott could experience difficulties in integrating geographically separated\\\
organizations,\\\
systems and facilities, and personnel with diverse backgrounds. Integration of an acquired business also may require management resources that otherwise would be available for ongoing development of\\\
Abbott's existing business. </FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Abbott\\\
may also dispose of or spin-off some of its businesses. Abbott may not complete these transactions in a timely manner, or at all, and may not realize their expected\\\
benefits. </FONT></P>\\\
\\\
<P ALIGN="CENTER"><FONT SIZE=2>9</FONT></P>\\\
\\\
<HR NOSHADE>\\\
<P style='page-break-before:always'></p>\\\
<!-- ZEQ.=2,SEQ=10,EFW="2167223",CP="ABBOTT LABORATORIES",DN="1",CHK=210487,FOLIO='9',FILE='DISK132:[06CHI8.06CHI1168]DI1168A.;6',USER='MWEINST',CD='13-FEB-2006;07:14' -->\\\
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->\\\
\\\
<P><FONT SIZE=2><A\\\
NAME="page_dk1168_1_10"> </A> </FONT></P>\\\
\\\
<!-- TOC_END -->\\\
\\\
<P><FONT SIZE=2><B>The expiration of patent protection and licenses may affect Abbott's future revenues and operating income.</B></FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Many\\\
of Abbott's businesses rely on patent and trademark and other intellectual property protection. Although most of the challenges to Abbott's intellectual property have come from\\\
other businesses, governments may also challenge intellectual property protections. To the extent Abbott's intellectual property is successfully challenged, invalidated, or circumvented or to the\\\
extent it does not allow Abbott to compete effectively, Abbott's business will suffer. To the extent that countries do not enforce Abbott's intellectual property rights or require compulsory licensing\\\
of its intellectual property, Abbott's future revenues and operating income will be reduced. </FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Abbott's\\\
principal patents and trademarks are described in greater detail in the sections captioned, "Patents, Trademarks, and Licenses" and "Financial Review," and litigation regarding\\\
these patents is described in the section captioned "Legal Proceedings." </FONT></P>\\\
\\\
<P><FONT SIZE=2><B>Competitors' intellectual property may prevent Abbott from selling its products or have a material adverse effect on Abbott's future profitability and financial\\\
condition.</B></FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Competitors\\\
may claim that an Abbott product infringes upon their intellectual property. A successful claim of patent or other intellectual property infringement against Abbott could\\\
adversely affect Abbott's profitability or financial condition, in some cases materially. Abbott cannot assure that it does not, in fact, infringe upon other's intellectual property. Resolving an\\\
intellectual property infringement claim can be costly and time consuming and may require Abbott to enter into royalty or license agreements. If this should be necessary, Abbott cannot guarantee that\\\
it would be able to obtain royalty or license agreements on commercially reasonable terms. A successful claim of patent or other intellectual property infringement could subject Abbott to significant\\\
damages or an injunction preventing the manufacture, sale or use of affected Abbott products. Any of these events could have a material adverse effect on Abbott's profitability and financial\\\
condition. </FONT></P>\\\
\\\
<P><FONT SIZE=2><B>Abbott is subject to cost-containment efforts.  </B></FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the United States and other countries, access to and the cost of human health care products continues to be subject to downward pressure on prices.\\\
Cost-containment efforts by the\\\
government and private organizations are described in greater detail in the section captioned "Regulation." </FONT></P>\\\
\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In\\\
markets outside the United States, Abbott's businesses have experienced downward pressure on product pricing. Many countries, directly or indirectly, through limitations on\\\
reimbursement or availability, control the selling price of most health care products. To the extent these cost containment efforts are not offset by greater patient access to healthcare or other\\\
factors, Abbott's future revenues and operating income will be reduced. </FONT></P>\\\
\\\
<P><FONT SIZE=2><B>Abbott is subject to numerous governmental regulations and it can be costly to comply with these regulations and to develop compliant products and\\\
processes.</B></FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Abbott's\\\
products are subject to rigorous regulation by the Federal Food and Drug Administration, and numerous other national, supranational, federal and state authorities. The process\\\
of obtaining regulatory approvals to market a drug or medical device, particularly from the FDA and certain governmental authorities outside the United States, can be costly and\\\
time-consuming, and approvals might not be granted for future products on a timely basis, if at all. Regulation is not static. The suspension, revocation, or adverse amendment of the\\\
authority necessary for manufacture, marketing, or sale, and the imposition of additional or different regulatory requirements, such as those affecting labeling can also occur. Delays in the receipt\\\
of, or failure to obtain approvals for, future products could result in delayed realization of product revenues and in substantial additional costs. </FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In\\\
addition, no assurance can be given that Abbott will remain in compliance with applicable FDA and other regulatory requirements once clearance or approval has been obtained for a\\\
product. These </FONT></P>\\\
\\\
<P ALIGN="CENTER"><FONT SIZE=2>10</FONT></P>\\\
\\\
<HR NOSHADE>\\\
<P style='page-break-before:always'></p>\\\
<!-- ZEQ.=1,SEQ=11,EFW="2167223",CP="ABBOTT LABORATORIES",DN="1",CHK=768884,FOLIO='10',FILE='DISK132:[06CHI8.06CHI1168]DK1168A.;9',USER='ABLIJDE',CD='20-FEB-2006;20:24' -->\\\
<A NAME="page_dk1168_1_11"> </A>\\\
<BR>\\\
\\\
<P><FONT SIZE=2>requirements\\\
include, among other things, regulations regarding manufacturing practices, product labeling and advertising and postmarketing reporting, including adverse event reports and field alerts\\\
due to manufacturing quality concerns. Many of Abbott's facilities and procedures and those of Abbott's suppliers are subject to ongoing regulation, including periodic inspection by the FDA and other\\\
regulatory authorities. For example, developers and manufacturers of health care products, including pharmaceutical products, medical devices, and nutritional products must comply with detailed\\\
regulations governing current good manufacturing, laboratory and clinical practices, including requirements relating to quality control and quality assurance. Abbott must incur expense and spend time\\\
and effort to ensure compliance with these complex regulations. In the past, Abbott's business has received notices alleging violations of these regulations, and Abbott has modified practices in\\\
response to these notices. </FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Abbott's\\\
manufacturing facilities and those of Abbott's suppliers could be subject to significant adverse regulatory actions in the future. These possible regulatory actions could\\\
include warning letters, fines, damages, injunctions, civil penalties, recalls, seizures of Abbott's products and criminal prosecution.\\\
These actions could result in, among other things, substantial modifications to Abbott's business practices and operations; refunds, recalls or seizures of Abbott's products; a total or partial\\\
shutdown of production in one or more of Abbott's facilities while Abbott remedies the alleged violation; the inability to obtain future pre-market clearances or approvals; and withdrawals\\\
or suspensions of current products from the market. Any of these events, in combination or alone, could disrupt Abbott's business and have a material adverse effect on Abbott's revenues, profitability\\\
and financial condition. </FONT></P>\\\
\\\
<P><FONT SIZE=2><B>Laws and regulations affecting government benefit programs could impose new obligations on Abbott, require Abbott to change its business practices, and restrict its operations\\\
in the future.</B></FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Abbott's\\\
industry is also subject to various federal and state laws pertaining to government benefit program reimbursement, price reporting and regulation, and health care fraud and\\\
abuse, including anti-kickback and false claims laws, the Medicaid Rebate Statute, the Veterans Health Care Act and individual state laws relating to pricing. Violations of these laws may\\\
be punishable by criminal and/or civil sanctions, including, in some instances, substantial fines, imprisonment and exclusion from participation in federal and state health care programs, including\\\
Medicare, Medicaid, and Veterans Administration health programs. These laws and regulations are broad in scope and they are subject to evolving interpretations, which could require Abbott to incur\\\
substantial costs associated with compliance or to alter one or more of its sales or marketing practices. In addition, violations of these laws, or allegations of such violations, could disrupt\\\
Abbott's business and result in a material adverse effect on Abbott's revenues, profitability and financial condition. </FONT></P>\\\
\\\
\\\
<P><FONT SIZE=2><B>If Abbott does not introduce new products in a timely manner, Abbott's products may become obsolete over time, customers may not buy Abbott's products, and Abbott's revenue and\\\
profitability may decline.</B></FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Demand\\\
for Abbott's products may change in ways Abbott does not anticipate. This could occur, for example, due to changing customer needs, the introduction by others of new products and\\\
technologies, or changing industry standards. Without the timely introduction of new products and enhancements, Abbott's products may become obsolete over time, causing Abbott's revenue and operating\\\
results to suffer. Even if Abbott succeeds in creating new product candidates, these candidates may not become commercially successful products. </FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The\\\
success of Abbott's new products will depend on a variety of factors, including Abbott's ability to: </FONT></P>\\\
\\\
<UL>\\\
<DL compact>\\\
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>properly\\\
anticipate and satisfy customer needs;\\\
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>innovate,\\\
develop, and manufacture new products in an economical and timely manner;\\\
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>differentiate\\\
Abbott's offerings from competitors' offerings;\\\
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>achieve\\\
positive clinical outcomes for new products; </FONT></DD></DL>\\\
</UL>\\\
<P ALIGN="CENTER"><FONT SIZE=2>11</FONT></P>\\\
\\\
<HR NOSHADE>\\\
<P style='page-break-before:always'></p>\\\
<!-- ZEQ.=2,SEQ=12,EFW="2167223",CP="ABBOTT LABORATORIES",DN="1",CHK=110863,FOLIO='11',FILE='DISK132:[06CHI8.06CHI1168]DK1168A.;9',USER='ABLIJDE',CD='20-FEB-2006;20:24' -->\\\
<A NAME="page_dk1168_1_12"> </A>\\\
<UL>\\\
<UL>\\\
</UL>\\\
<DL compact>\\\
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>meet\\\
safety requirements and other regulatory requirements of government agencies;\\\
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>avoid\\\
infringing the proprietary rights of third parties; and\\\
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>establish\\\
and maintain its intellectual property rights. </FONT></DD></DL>\\\
</UL>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even\\\
if Abbott successfully develops new products or enhancements or new generations of Abbott's existing products, these new products or enhancements or new generations of Abbott's\\\
existing products may be quickly rendered obsolete by changing customer preferences or the introduction by Abbott's competitors of products embodying new technologies or features. Finally, innovations\\\
may not be accepted quickly in the marketplace because of, among other things, entrenched patterns of clinical practice, the need for regulatory clearance, and uncertainty over third-party\\\
reimbursement. </FONT></P>\\\
\\\
<P><FONT SIZE=2><B>The manufacture of many of Abbott's products is a highly exacting and complex process, and if Abbott or one of its suppliers encounters problems manufacturing products,\\\
Abbott's business could suffer.</B></FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The\\\
manufacture of many of Abbott's products is a highly exacting and complex process, due in part to strict regulatory requirements, which govern their manufacture. Problems may arise\\\
during manufacturing for a variety of reasons, including equipment malfunction, failure to follow specific protocols and procedures, problems with raw materials, natural disasters and environmental\\\
factors. If problems arise during the production of a batch of product, that batch of product may have to be\\\
discarded. This could, among other things, lead to increased costs, lost revenue, damage to customer relations, time and expense spent investigating the cause and, depending on the cause, similar\\\
losses with respect to other batches or products. If problems are not discovered before the product is released to the market, recall and product liability costs may also be incurred. To the extent\\\
Abbott or one of its suppliers experiences significant manufacturing problems, this could have a material adverse effect on Abbott's revenues and profitability. </FONT></P>\\\
\\\
<P><FONT SIZE=2><B>The international nature of Abbott's business subjects it to additional business risks that may cause its revenue and profitability to decline.</B></FONT></P>\\\
\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Abbott's\\\
business is subject to risks associated with doing business internationally. Sales outside of the United States make up more than 40% of Abbott's net sales. The risks associated\\\
with Abbott's operations outside the United States include: </FONT></P>\\\
\\\
<UL>\\\
<DL compact>\\\
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>changes\\\
in foreign medical reimbursement policies and programs;\\\
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>multiple\\\
foreign regulatory requirements that are subject to change and that could restrict Abbott's ability to manufacture and sell its products;\\\
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>differing\\\
local product preferences and product requirements;\\\
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>fluctuations\\\
in foreign currency exchange rates and in interest rates;\\\
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>trade\\\
protection measures and import or export licensing requirements;\\\
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>difficulty\\\
in establishing, staffing, and managing foreign operations;\\\
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>differing\\\
labor regulations;\\\
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>potentially\\\
negative consequences from changes in or interpretations of tax laws;\\\
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>political\\\
and economic instability;\\\
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>inflation,\\\
recession, interest rate fluctuations, and actual or anticipated military or political conflicts; and\\\
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>diminished\\\
protection of intellectual property in some countries. </FONT></DD></DL>\\\
</UL>\\\
<P ALIGN="CENTER"><FONT SIZE=2>12</FONT></P>\\\
\\\
<HR NOSHADE>\\\
<P style='page-break-before:always'></p>\\\
<!-- ZEQ.=3,SEQ=13,EFW="2167223",CP="ABBOTT LABORATORIES",DN="1",CHK=372239,FOLIO='12',FILE='DISK132:[06CHI8.06CHI1168]DK1168A.;9',USER='ABLIJDE',CD='20-FEB-2006;20:24' -->\\\
<A NAME="page_dk1168_1_13"> </A>\\\
<UL>\\\
<UL>\\\
</UL>\\\
</UL>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These\\\
risks may, individually or in the aggregate, have a material adverse effect on Abbott's revenues and profitability. </FONT></P>\\\
\\\
<P><FONT SIZE=2><B>Significant safety issues could arise for Abbott's products, which could have a material adverse effect on Abbott's revenues and financial condition.</B></FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All\\\
health care products, including pharmaceutical products, medical products, and nutritionals, receive regulatory approval based on data obtained in controlled clinical trials of\\\
limited duration. Following regulatory approval, these products will be used over longer periods of time in many patients. Investigators may also conduct additional, and perhaps more extensive,\\\
studies or studies for different indications. If new safety issues are reported, Abbott may be required to amend the conditions of use for a product. For example, Abbott may be required to provide\\\
additional warnings on a product's label or narrow its approved indication, either of which could reduce the product's market acceptance. If serious safety issues with an Abbott product arise, sales\\\
of the product could be halted by Abbott or by regulatory authorities. </FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In\\\
addition, in the ordinary course of business, Abbott is the subject of product liability claims and lawsuits alleging that its products have resulted or could result in an unsafe\\\
condition or injury to patients. Product liability claims and lawsuits and safety alerts or product recalls, regardless of their ultimate outcome, may have a material adverse effect on Abbott's\\\
business and reputation and on\\\
Abbott's ability to attract and retain customers. Product liability claims could have a material adverse effect on Abbott's profitability and financial condition. </FONT></P>\\\
\\\
<P><FONT SIZE=2><B>Abbott faces significant competition and may not be able to compete effectively.</B></FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Abbott\\\
competes with many companies ranging from other multinational companies to small start-up companies. Competition takes many forms, including responding to pricing\\\
pressures from managed care groups and government agencies, the development of new products by competitors having lower prices or superior performance or that are otherwise competitive with Abbott's\\\
current products, generic competition when Abbott's products lose their patent or regulatory protection, technological advances, patents and registrations obtained by competitors, and business\\\
combinations among Abbott's competitors or major customers. Abbott's present or future products could be rendered obsolete or uneconomical as the result of this competition. Abbott's failure to\\\
compete effectively could cause it to lose market share to its competitors and/or have a material adverse effect on its revenues and profitability. </FONT></P>\\\
\\\
<P><FONT SIZE=2><B>External economic forces, over which Abbott has no control, can have a material adverse effect on Abbott's future profitability and financial condition.</B></FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Many\\\
external economic forces can affect Abbott's profitability and its financial condition. For example, to calculate its cost for pension and post-employment benefits,\\\
Abbott must use the long-term assumptions it has developed with the assistance of its actuaries. These include assumptions regarding the health care cost trend rate, discount (interest)\\\
rate, and the expected return on plan assets. Similarly, to determine its stock-based compensation costs, Abbott must develop assumptions regarding the volatility of Abbott's common shares, option\\\
life, the associated tax benefit, and discount (interest) rate. These assumptions are based on an analysis of external economic factors over which Abbott has no control. To the extent these factors\\\
change over time or actual results differ from these assumptions, Abbott may incur increased costs, some of which may be material. </FONT></P>\\\
\\\
\\\
-\
\\\
<P><FONT SIZE=2><B>Principal Market  </B></FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The principal market for Abbott's common shares is the New York Stock Exchange. Shares are also listed on the Chicago Stock Exchange and the Pacific Exchange and\\\
are traded on the Boston, Cincinnati, and Philadelphia Exchanges. Outside the United States, Abbott's shares are listed on the London Stock Exchange and the Swiss Stock Exchange. </FONT></P>\\\
\\\
<!-- User-specified TAGGED TABLE -->\\\
<DIV ALIGN="CENTER"><TABLE WIDTH="80%" BORDER=0 CELLSPACING=0 CELLPADDING=0>\\\
<TR VALIGN="BOTTOM">\\\
<TH WIDTH="56%" ALIGN="LEFT"><FONT SIZE=2>&nbsp;</FONT><BR></TH>\\\
<TH WIDTH="3%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH COLSPAN=7 ALIGN="CENTER"><FONT SIZE=1><B>Market Price Per Share</B></FONT><HR NOSHADE></TH>\\\
</TR>\\\
<TR VALIGN="BOTTOM">\\\
<TH WIDTH="56%" ALIGN="LEFT"><FONT SIZE=1>&nbsp;</FONT><BR></TH>\\\
<TH WIDTH="3%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH COLSPAN=3 ALIGN="CENTER"><FONT SIZE=1><B>2005</B></FONT><HR NOSHADE></TH>\\\
<TH WIDTH="3%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH COLSPAN=3 ALIGN="CENTER"><FONT SIZE=1><B>2004</B></FONT><HR NOSHADE></TH>\\\
</TR>\\\
<TR VALIGN="BOTTOM">\\\
<TH WIDTH="56%" ALIGN="LEFT"><FONT SIZE=1>&nbsp;</FONT><BR></TH>\\\
<TH WIDTH="3%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH WIDTH="8%" ALIGN="CENTER"><FONT SIZE=1><B>high</B></FONT><HR NOSHADE></TH>\\\
<TH WIDTH="3%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH WIDTH="8%" ALIGN="CENTER"><FONT SIZE=1><B>low</B></FONT><HR NOSHADE></TH>\\\
<TH WIDTH="3%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH WIDTH="8%" ALIGN="CENTER"><FONT SIZE=1><B>high</B></FONT><HR NOSHADE></TH>\\\
<TH WIDTH="3%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH WIDTH="8%" ALIGN="CENTER"><FONT SIZE=1><B>low</B></FONT><HR NOSHADE></TH>\\\
</TR>\\\
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">\\\
<TD WIDTH="56%"><FONT SIZE=2>First Quarter</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>48.16</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>43.34</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>47.25</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>39.28</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="White" VALIGN="TOP">\\\
<TD WIDTH="56%"><FONT SIZE=2>Second Quarter</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>49.98</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>45.98</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>44.67</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>39.43</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">\\\
<TD WIDTH="56%"><FONT SIZE=2>Third Quarter</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>50.00</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>41.57</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>43.20</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>38.26</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="White" VALIGN="TOP">\\\
<TD WIDTH="56%"><FONT SIZE=2>Fourth Quarter</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>44.36</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>37.50</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>47.63</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>40.25</FONT></TD>\\\
</TR>\\\
</TABLE></DIV>\\\
<!-- end of user-specified TAGGED TABLE -->\\\
\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Market\\\
prices are as reported by the New York Stock Exchange composite transaction reporting system. On April&nbsp;30, 2004, Abbott spun off all of the outstanding common shares of\\\
Hospira. For every 10 Abbott common shares held at the close of business on April&nbsp;22, 2004, Abbott shareholders received one common share of Hospira stock on April&nbsp;30, 2004. In the table\\\
above, market prices include the value of the Hospira business through the date of the spin-off. Subsequent to the spin-off, the value of Abbott shares no longer includes the\\\
value of the Hospira business. </FONT></P>\\\
\\\
<P><FONT SIZE=2><B>Shareholders  </B></FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There were 82,237 shareholders of record of Abbott common shares as of December&nbsp;31, 2005. </FONT></P>\\\
\\\
<P><FONT SIZE=2><B>Dividends  </B></FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Quarterly dividends of $.275 per share and $.26 per share were declared on common shares in 2005 and 2004, respectively. In addition, as noted above, a special\\\
dividend distribution of shares of Hospira,&nbsp;Inc. occurred in the second quarter of 2004. For every 10 Abbott common shares held at the close of business on April&nbsp;22, 2004, Abbott\\\
shareholders received one share of Hospira common stock on April&nbsp;30, 2004. </FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Abbott\\\
Laboratories is an Illinois High Impact Business (HIB) and is located in a federal Foreign Trade Sub-Zone (Sub-Zone&nbsp;22F). Dividends may be eligible\\\
for a subtraction from base income for Illinois income tax purposes. If you have questions, please contact your tax advisor. </FONT></P>\\\
\\\
<P ALIGN="CENTER"><FONT SIZE=2>26</FONT></P>\\\
\\\
<HR NOSHADE>\\\
<P style='page-break-before:always'></p>\\\
<!-- ZEQ.=1,SEQ=27,EFW="2167223",CP="ABBOTT LABORATORIES",DN="1",CHK=998110,FOLIO='26',FILE='DISK132:[06CHI8.06CHI1168]DQ1168A.;16',USER='MBLOUNT',CD='13-FEB-2006;07:24' -->\\\
<A NAME="page_dq1168_1_27"> </A>\\\
\\\
<P><FONT SIZE=2><B>Issuer Purchases of Equity Securities  </B></FONT></P>\\\
\\\
<!-- User-specified TAGGED TABLE -->\\\
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>\\\
<TR VALIGN="BOTTOM">\\\
<TH WIDTH="30%" ALIGN="LEFT"><FONT SIZE=1><B>Period<BR> </B></FONT><HR NOSHADE></TH>\\\
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH WIDTH="12%" ALIGN="CENTER"><FONT SIZE=1><B>(a) Total Number of Shares (or Units) Purchased</B></FONT><HR NOSHADE></TH>\\\
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>(b) Average Price Paid per Share (or Unit)</B></FONT><HR NOSHADE></TH>\\\
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH WIDTH="12%" ALIGN="CENTER"><FONT SIZE=1><B>(c) Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plan or Programs</B></FONT><HR NOSHADE></TH>\\\
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH WIDTH="18%" ALIGN="CENTER"><FONT SIZE=1><B>(d) Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs</B></FONT><HR NOSHADE></TH>\\\
<TH WIDTH="11%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
</TR>\\\
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">\\\
<TD WIDTH="30%"><FONT SIZE=2>October 1, 2005 &#151;<BR>\\\
October 31, 2005</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=2>100,420</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2><SUP>1</SUP></FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>42.61</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=2>0</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="18%" ALIGN="RIGHT"><FONT SIZE=2>32,558,000</FONT></TD>\\\
<TD WIDTH="11%"><FONT SIZE=2><SUP>2</SUP></FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="White" VALIGN="BOTTOM">\\\
<TD WIDTH="30%"><FONT SIZE=2>November 1, 2005 &#151;<BR>\\\
November 30, 2005</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=2>1,132,311</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2><SUP>1</SUP></FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>38.742</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=2>1,040,000</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="18%" ALIGN="RIGHT"><FONT SIZE=2>31,518,000</FONT></TD>\\\
<TD WIDTH="11%"><FONT SIZE=2><SUP>2</SUP></FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">\\\
<TD WIDTH="30%"><FONT SIZE=2>December 1, 2005 &#151;<BR>\\\
December 31, 2005</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=2>11,617,053</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2><SUP>1</SUP></FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>40.062</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=2>11,482,444</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="18%" ALIGN="RIGHT"><FONT SIZE=2>20,035,556</FONT></TD>\\\
<TD WIDTH="11%"><FONT SIZE=2><SUP>2</SUP></FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="White" VALIGN="BOTTOM">\\\
<TD WIDTH="30%"><FONT SIZE=2>Total</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=2>12,849,784</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2><SUP>1</SUP></FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>39.966</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=2>12,522,444</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="18%" ALIGN="RIGHT"><FONT SIZE=2>20,035,556</FONT></TD>\\\
<TD WIDTH="11%"><FONT SIZE=2><SUP>2</SUP></FONT></TD>\\\
</TR>\\\
</TABLE>\\\
<!-- end of user-specified TAGGED TABLE -->\\\
\\\
<UL>\\\
<DL compact>\\\
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>1.</FONT></DT><DD><FONT SIZE=2>These\\\
shares represent:\\\
<BR><BR></FONT>\\\
<DL compact>\\\
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(i)</FONT></DT><DD><FONT SIZE=2>the\\\
shares surrendered to Abbott to satisfy tax withholding obligations in connection with the vesting of restricted stock&nbsp;&#151; 0 in October; 3,453 in\\\
November; and 16,083 in December;\\\
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(ii)</FONT></DT><DD><FONT SIZE=2>the\\\
shares deemed surrendered to Abbott to pay the exercise price and to satisfy tax withholding obligations in connection with the exercise of employee stock\\\
options&nbsp;&#151; 90,420 in October; 78,858 in November; and 76,526 in December; and\\\
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(iii)</FONT></DT><DD><FONT SIZE=2>the\\\
shares purchased on the open market for the benefit of participants in the Abbott Canada Stock Retirement Plan&nbsp;&#151; 10,000 in October; 10,000 in\\\
November; and 42,000 in December.\\\
<BR><BR></FONT></DD></DL>\\\
</DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>2.</FONT></DT><DD><FONT SIZE=2>On\\\
October&nbsp;14, 2004, Abbott announced that Abbott's board of directors approved the purchase of up to 50&nbsp;million of its common shares. </FONT></DD></DL>\\\
</UL>\\\
\\\
<P><FONT SIZE=2><A\\\
NAME="dq1168_item_6._selected_financial_data"> </A>\\\
<A NAME="toc_dq1168_3"> </A>\\\
<BR></FONT><FONT SIZE=2><B>ITEM 6.&nbsp;&nbsp;&nbsp;&nbsp;SELECTED FINANCIAL DATA    <BR>    </B></FONT></P>\\\
\\\
<!-- User-specified TAGGED TABLE -->\\\
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>\\\
<TR VALIGN="BOTTOM">\\\
<TH WIDTH="36%" ALIGN="LEFT"><FONT SIZE=2>&nbsp;</FONT><BR></TH>\\\
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH COLSPAN=14 ALIGN="CENTER"><FONT SIZE=1><B>Year ended December 31</B></FONT><HR NOSHADE></TH>\\\
<TH WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TH>\\\
</TR>\\\
<TR VALIGN="BOTTOM">\\\
<TH WIDTH="36%" ALIGN="LEFT"><FONT SIZE=2>&nbsp;</FONT><BR></TH>\\\
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>2005</B></FONT><HR NOSHADE></TH>\\\
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>2004</B></FONT><HR NOSHADE></TH>\\\
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>2003</B></FONT><HR NOSHADE></TH>\\\
<TH WIDTH="3%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>2002</B></FONT><HR NOSHADE></TH>\\\
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>2001</B></FONT><HR NOSHADE></TH>\\\
<TH WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TH>\\\
</TR>\\\
<TR VALIGN="BOTTOM">\\\
<TH WIDTH="36%" ALIGN="LEFT"><FONT SIZE=2>&nbsp;</FONT><BR></TH>\\\
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH COLSPAN=14 ALIGN="CENTER"><FONT SIZE=1><B><I>(dollars in millions, except per share data)<BR> </I></B></FONT><BR></TH>\\\
<TH WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TH>\\\
</TR>\\\
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">\\\
<TD WIDTH="36%"><FONT SIZE=2>Net sales (a)</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>22,337.8</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>19,680.0</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>17,280.3</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>15,279.5</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>13,918.5</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="White" VALIGN="BOTTOM">\\\
<TD WIDTH="36%"><FONT SIZE=2>Earnings from continuing operations</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>3,372.1</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>3,175.8</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>2,504.7</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>2,547.0</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>1,277.7</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">\\\
<TD WIDTH="36%"><FONT SIZE=2>Net earnings</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>3,372.1</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>3,235.9</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>2,753.2</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>2,793.7</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>1,550.4</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>(b)</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="White" VALIGN="BOTTOM">\\\
<TD WIDTH="36%"><FONT SIZE=2>Basic earnings per common share from continuing operations</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>2.17</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>2.03</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>1.60</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>1.63</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>0.82</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">\\\
<TD WIDTH="36%"><FONT SIZE=2>Basic earnings per common share</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>2.17</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>2.07</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>1.76</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>1.79</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>1.00</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>(b)</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="White" VALIGN="BOTTOM">\\\
<TD WIDTH="36%"><FONT SIZE=2>Diluted earnings per common share from continuing operations</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>2.16</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>2.02</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>1.59</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>1.62</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>0.82</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">\\\
<TD WIDTH="36%"><FONT SIZE=2>Diluted earnings per common share</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>2.16</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>2.06</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>1.75</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>1.78</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>0.99</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>(b)</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="White" VALIGN="BOTTOM">\\\
<TD WIDTH="36%"><FONT SIZE=2>Total assets</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>29,141.2</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>28,767.5</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>26,039.3</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>23,592.7</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>22,755.5</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">\\\
<TD WIDTH="36%"><FONT SIZE=2>Long-term debt</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>4,571.5</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>4,787.9</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>3,452.3</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>4,274.0</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>4,335.5</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="White" VALIGN="BOTTOM">\\\
<TD WIDTH="36%"><FONT SIZE=2>Cash dividends declared per common share</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>1.10</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>1.04</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>0.98</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>0.94</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>0.84</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
</TR>\\\
</TABLE>\\\
<!-- end of user-specified TAGGED TABLE -->\\\
\\\
<DL compact>\\\
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD><FONT SIZE=2>Net\\\
sales for 2003 and prior years have been adjusted to reflect the presentation of Hospira,&nbsp;Inc. as a discontinued operation.\\\
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD><FONT SIZE=2>In\\\
2001, Abbott recorded a pre-tax charge of $1,330 for acquired in-process research and development related to acquisitions of the pharmaceutical business of\\\
BASF and of Vysis,&nbsp;Inc. </FONT></DD></DL>\\\
<P ALIGN="CENTER"><FONT SIZE=2>27</FONT></P>\\\
\\\
<HR NOSHADE>\\\
<P style='page-break-before:always'></p>\\\
<!-- ZEQ.=2,SEQ=28,EFW="2167223",CP="ABBOTT LABORATORIES",DN="1",CHK=442772,FOLIO='27',FILE='DISK132:[06CHI8.06CHI1168]DQ1168A.;16',USER='MBLOUNT',CD='13-FEB-2006;07:24' -->\\\
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->\\\
\\\
<P><FONT SIZE=2><A\\\
NAME="page_ds1168_1_28"> </A> </FONT></P>\\\
\\\
<!-- TOC_END -->\\\
\\\
\\\
<P><FONT SIZE=2><A\\\
NAME="ds1168_item_7._management_s_discussio__ite03668"> </A>\\\
<A NAME="toc_ds1168_1"> </A>\\\
<BR></FONT><FONT SIZE=2><B>ITEM 7.&nbsp;&nbsp;&nbsp;&nbsp;MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS    <BR>    </B></FONT></P>\\\
\\\
<P ALIGN="CENTER"><FONT SIZE=2><B>Financial Review  </B></FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Abbott's revenues are derived primarily from the sale of a broad line of health care products under short-term receivable arrangements. Patent\\\
protection and licenses, technological and performance features, and inclusion of Abbott's products under a contract or by a pharmacy benefit manager most impact which products are sold; price\\\
controls, competition and rebates most impact the net selling prices of products; and foreign currency translation impacts the measurement of net sales. Abbott's primary products are prescription\\\
pharmaceuticals, nutritional products and diagnostic testing products. Abbott also owns 50&nbsp;percent of TAP Pharmaceutical Products&nbsp;Inc. (TAP) that Abbott accounts for on the equity\\\
method. </FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The\\\
worldwide launch of </FONT><FONT SIZE=2><I>HUMIRA</I></FONT><FONT SIZE=2>, the spin-off of Hospira, integration and restructuring activities and the loss of patent\\\
protection for some products have impacted Abbott's sales, costs and financial position over the last three years. </FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subsequent\\\
to Abbott's 2001 acquisition of the Knoll pharmaceutical business, which significantly increased the scale of Abbott's pharmaceutical business, Abbott focused on reorganizing\\\
and growing its global pharmaceutical business. Abbott has established a global research and development organization and a global manufacturing and distribution organization to serve its domestic and\\\
international commercial pharmaceutical operations. Pharmaceutical research and development is focused on five therapeutic areas &#151; immunology, oncology, neuroscience, diabetes/metabolism,\\\
and viral diseases. U.S. commercial pharmaceutical operations are focused mainly on primary care and specialty pharmaceuticals. In 2003, Abbott began the worldwide launch of </FONT> <FONT SIZE=2><I>HUMIRA</I></FONT><FONT SIZE=2>, which increased its\\\
worldwide sales to $1.4&nbsp;billion in 2005 compared to $852&nbsp;million in 2004. In 2005, Abbott and Boehringer\\\
Ingelheim (BI) amended their agreement whereby Abbott distributed and promoted BI products. Effective January&nbsp;1, 2006, Abbott will no longer distribute BI products but will receive residual\\\
commissions. Abbott's gross margins for BI products from the prior agreement in effect through December&nbsp;31, 2005 were substantially lower than its average gross margin. 2005 sales of BI\\\
products were $2.3&nbsp;billion. Increased generic competition resulted in U.S. sales of </FONT><FONT SIZE=2><I>Synthroid</I></FONT><FONT SIZE=2> declining 22&nbsp;percent in 2005 while holding a\\\
36&nbsp;percent market share. </FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In\\\
2004, Abbott separated its diagnostic segment into four separate divisions &#151; immunoassay/hematology, diabetes care, molecular, and point of care &#151; to better\\\
focus on commercial and scientific opportunities. In early 2004, Abbott acquired TheraSense for $1.2&nbsp;billion, and began to integrate it with Abbott's diabetes care business. In late 2003,\\\
Abbott was informed by the FDA that it may distribute the immunoassay products in the U.S. that were impacted by regulatory restrictions imposed in 1999. Net sales and profits for this business\\\
declined over the restricted period, but stabilized in 2004 and 2005. In 2005, Abbott diagnostics launched more than 50 new products. In the Ross segment in 2003, Abbott settled its portion of an\\\
industry-wide investigation of the enteral nutritional business for $614&nbsp;million. </FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In\\\
2004, Abbott completed the spin-off of Hospira, Abbott's former hospital products business. Annual sales of Hospira were approximately $2.4&nbsp;billion. As part of the\\\
spin-off, Hospira assumed $700&nbsp;million of debt. The historical operating and cash flow results of Hospira are presented as discontinued operations. Hospira is contractually\\\
obligated to purchase the international hospital assets and operations that were not included in the spin-off. The legal transfer of certain remaining operations and assets (net of\\\
liabilities) outside the United States is expected to occur in the first half of 2006. </FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In\\\
early 2006, Abbott reached agreement to acquire Guidant's vascular intervention and endovascular solutions businesses, subject to Boston Scientific's acquisition of Guidant. Guidant's\\\
annual revenues from these businesses are approximately $1&nbsp;billion. The purchase price would be $4.1&nbsp;billion, plus contingent milestone payments of $500&nbsp;million. </FONT></P>\\\
\\\
<P ALIGN="CENTER"><FONT SIZE=2>28</FONT></P>\\\
\\\
<HR NOSHADE>\\\
<P style='page-break-before:always'></p>\\\
<!-- ZEQ.=1,SEQ=29,EFW="2167223",CP="ABBOTT LABORATORIES",DN="1",CHK=749299,FOLIO='28',FILE='DISK132:[06CHI8.06CHI1168]DS1168A.;16',USER='MBLOUNT',CD='21-FEB-2006;11:56' -->\\\
<A NAME="page_ds1168_1_29"> </A>\\\
<BR>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TAP's\\\
contribution to Abbott's earnings declined in 2004 and 2003. A part of the decline was due to increased competition for </FONT><FONT SIZE=2><I>Prevacid</I></FONT><FONT SIZE=2>,\\\
TAP's largest selling product, and due to market contraction for prescription proton pump inhibitors. In 2004, TAP recorded additional litigation reserves of $125&nbsp;million for an anticipated\\\
legal settlement. </FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Abbott's\\\
short- and long-term debt totaled $6.6&nbsp;billion at December&nbsp;31, 2005, largely incurred to finance acquisitions. Operating cash flows in excess of\\\
capital expenditures and cash dividends have allowed Abbott to reduce debt and fund acquisitions over the last three years. At December&nbsp;31, 2005, Abbott's long-term debt rating was\\\
AA by Standard and Poor's and A1 by Moody's Investors Service. </FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In\\\
2006, Abbott will focus on several key initiatives. In the global pharmaceutical business, Abbott will launch newly approved indications for </FONT> <FONT SIZE=2><I>HUMIRA</I></FONT><FONT SIZE=2>. Abbott will also focus on appropriate market support\\\
for </FONT><FONT SIZE=2><I>Synthroid</I></FONT><FONT SIZE=2>, which became subject to\\\
generic U.S. competition in mid-2004, and for\\\
sevoflurane, which became subject to generic competition in December&nbsp;2005. In 2005, TAP received an approvable letter from the FDA for febuxostat. Contingent upon FDA approval, TAP plans to\\\
launch febuxostat in 2006. Pharmaceutical research and development efforts will continue to be focused in the five therapeutic areas noted above with a significant portion of the development\\\
expenditures allocated to new </FONT><FONT SIZE=2><I>HUMIRA</I></FONT><FONT SIZE=2> indications. Abbott expects to submit additional pharmaceutical regulatory filings in 2006. In the immunoassay\\\
business, attention will be focused on improving revenue growth by capitalizing on recent product launches, including the U.S. launch of the blood screening system, </FONT> <FONT SIZE=2><I>PRISM</I></FONT><FONT SIZE=2>, launching additional products,\\\
and commercial execution of the existing broad product portfolio. In the hematology business, attention will be\\\
focused on the continued launch of </FONT><FONT SIZE=2><I>CELL-DYN Sapphire</I></FONT><FONT SIZE=2> and other analyzers</FONT><FONT SIZE=2><I>.</I></FONT><FONT SIZE=2> For diabetes care,\\\
Abbott will continue the launch of </FONT><FONT SIZE=2><I>FreeStyle Connect</I></FONT><FONT SIZE=2> and Abbott anticipates the approval of </FONT><FONT SIZE=2><I>FreeStyle\\\
Navigator</I></FONT><FONT SIZE=2> in 2006. Upon closure of the acquisition of Guidant's vascular business, planning for its integration would be a key activity in the vascular business. Focus in this\\\
business will also be on the 2005 launch of </FONT><FONT SIZE=2><I>Xact</I></FONT><FONT SIZE=2> Carotid Stent and </FONT><FONT SIZE=2><I>Emboshield Embolic Protection System</I></FONT><FONT SIZE=2>\\\
and the projected approval of </FONT><FONT SIZE=2><I>ZoMaxx</I></FONT><FONT SIZE=2>, Abbott's drug-eluting stent, in Europe. With a greater focus on consumer marketing, Ross will maximize\\\
the strength of its core brands and further develop its healthy-living market presence. In the other business segments, Abbott will focus on developing or acquiring differentiated technologies in\\\
higher growth segments of those markets. </FONT></P>\\\
\\\
<P><FONT SIZE=2><B>Critical Accounting Policies  </B></FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT\\\
SIZE=2><I>Sales Rebates</I></FONT><FONT SIZE=2> &#151; Approximately 40&nbsp;percent of Abbott's consolidated gross revenues are subject to various forms of\\\
rebates and allowances that Abbott records as reductions of revenues at the time of sale. Most of these rebates and allowances are in two of Abbott's domestic segments &#151; the Pharmaceutical\\\
Products segment and the Ross Products segment. Abbott provides rebates to pharmacy benefit management companies, to state agencies which administer the federal Medicaid program and the Special\\\
Supplemental Food Program for Women, Infants, and Children (WIC), wholesalers, group purchasing organizations, and other government agencies and private entities. Rebate amounts are usually based upon\\\
the volume of purchases using contractual or statutory prices for a product. Factors used in the rebate calculations include the identification of which products have been sold subject to a rebate,\\\
which customer or government agency price terms apply, and the estimated lag time between sale and payment of a rebate. Using historical trends, adjusted for current changes, Abbott estimates the\\\
amount of the rebate that will be paid, and records the liability as a reduction of gross sales when Abbott records its sale of the product. Settlement of the rebate generally occurs from two to\\\
24&nbsp;months after sale. Abbott regularly analyzes the historical rebate trends and makes adjustments to reserves for changes in trends and terms of rebate programs. Rebates and chargebacks\\\
charged against gross sales in 2005, 2004 and 2003 amounted to approximately $2.5&nbsp;billion, $2.4&nbsp;billion and $1.8&nbsp;billion, respectively, or 22.9&nbsp;percent,\\\
25.6&nbsp;percent, and 22.7&nbsp;percent, respectively, based on gross sales of approximately $10.9&nbsp;billion, $9.3&nbsp;billion and $8.0&nbsp;billion, respectively, subject to rebate. A\\\
one-percentage point increase in the percentage of rebates to related gross sales would decrease net sales and operating earnings by approximately $109&nbsp;million in 2005. Other </FONT></P>\\\
\\\
<P ALIGN="CENTER"><FONT SIZE=2>29</FONT></P>\\\
\\\
<HR NOSHADE>\\\
<P style='page-break-before:always'></p>\\\
<!-- ZEQ.=2,SEQ=30,EFW="2167223",CP="ABBOTT LABORATORIES",DN="1",CHK=602374,FOLIO='29',FILE='DISK132:[06CHI8.06CHI1168]DS1168A.;16',USER='MBLOUNT',CD='21-FEB-2006;11:56' -->\\\
<A NAME="page_ds1168_1_30"> </A>\\\
\\\
<P><FONT SIZE=2>allowances\\\
charged against gross sales were approximately $284&nbsp;million, $233&nbsp;million and $191&nbsp;million for cash discounts in 2005, 2004 and 2003, respectively, and\\\
$162&nbsp;million, $163&nbsp;million and $171&nbsp;million for returns in 2005, 2004 and 2003, respectively. Cash discounts are known within 15 to 30&nbsp;days of sale, and therefore can be\\\
reliably estimated. Returns can be reliably estimated because Abbott's historical returns are low, and because sales returns terms and other sales terms have remained relatively unchanged for several\\\
periods. </FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Management\\\
analyzes the adequacy of ending accrual balances each quarter. In the Ross nutritional business, management uses both internal and external data available to estimate the\\\
level of inventory in the distribution channel. Management internally estimates the inventory in the retail channel that is not on the retail shelf. A third party continuously measures time on the\\\
retail shelf, which is a relatively significant portion of the time inventory is in the distribution channel. Except for a transition period before or after a change in the supplier for the WIC\\\
business in a state, inventory in the distribution channel does not vary substantially. Management also estimates the states' processing lag time based on claims data. In addition, internal processing\\\
time is a factor in estimating the accrual. In the WIC business, the state where the sale is made, which is the determining factor for the applicable price, is reliably estimable. Estimates are\\\
required for the amount of WIC sales within each state where Abbott has the WIC business. External data sources utilized for that estimate are participant data from the U.S. Department of Agriculture\\\
(USDA), which administers the WIC program, participant data from some of the states, and internally administered market surveys. The USDA has been making its data available for many years. Internal\\\
data includes historical redemption rates and pricing data. At December&nbsp;31, 2005, Ross had the exclusive WIC business in 11 states. </FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In\\\
the domestic pharmaceutical business, the most significant charges against gross sales are for Medicaid Rebates, Pharmacy Benefit Manager Rebates and Wholesaler Chargebacks. In order\\\
to evaluate the adequacy of the ending accrual balances, management uses both internal and external estimates of the level of inventory in the distribution channel and the rebate claims processing lag\\\
time. External data sources used to estimate the inventory in the distribution channel include inventory levels periodically reported by wholesalers and third party market data purchased by Abbott.\\\
Management estimates the processing lag time based on periodic sampling of claims data. To estimate the price rebate percentage, systems and calculations are used to track sales by product by customer\\\
and to estimate the contractual or statutory price. Abbott's systems and calculations have developed over time as rebates have become more significant, and Abbott believes they are reliable. </FONT></P>\\\
\\\
<P ALIGN="CENTER"><FONT SIZE=2>30</FONT></P>\\\
\\\
<HR NOSHADE>\\\
<P style='page-break-before:always'></p>\\\
<!-- ZEQ.=3,SEQ=31,EFW="2167223",CP="ABBOTT LABORATORIES",DN="1",CHK=783956,FOLIO='30',FILE='DISK132:[06CHI8.06CHI1168]DS1168A.;16',USER='MBLOUNT',CD='21-FEB-2006;11:56' -->\\\
<A NAME="page_ds1168_1_31"> </A>\\\
<BR>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The\\\
following table is an analysis of the four largest rebate accruals, which comprise approximately 80&nbsp;percent of the consolidated rebate provisions charged against revenues in\\\
2005. Remaining rebate provisions charged against gross sales are not significant in the determination of operating earnings. (</FONT><FONT SIZE=2><I>dollars in thousands</I></FONT><FONT SIZE=2>) </FONT></P>\\\
\\\
<!-- User-specified TAGGED TABLE -->\\\
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>\\\
<TR VALIGN="BOTTOM">\\\
<TH WIDTH="42%" ALIGN="LEFT"><FONT SIZE=2>&nbsp;</FONT><BR></TH>\\\
<TH WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TH>\\\
<TH COLSPAN=2 ALIGN="LEFT"><FONT SIZE=2>&nbsp;</FONT><BR></TH>\\\
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH COLSPAN=8 ALIGN="CENTER"><FONT SIZE=1><B>Pharmaceutical Products</B></FONT><HR NOSHADE></TH>\\\
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
</TR>\\\
<TR VALIGN="BOTTOM">\\\
<TH WIDTH="42%" ALIGN="LEFT"><FONT SIZE=1>&nbsp;</FONT><BR></TH>\\\
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>Ross<BR>\\\
Products<BR>\\\
WIC<BR>\\\
Rebates</B></FONT><HR NOSHADE></TH>\\\
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>Medicaid<BR>\\\
Rebates</B></FONT><HR NOSHADE></TH>\\\
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>Pharmacy<BR>\\\
Benefit<BR>\\\
Manager<BR>\\\
Rebates</B></FONT><HR NOSHADE></TH>\\\
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>Wholesaler<BR>\\\
Chargebacks</B></FONT><HR NOSHADE></TH>\\\
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
</TR>\\\
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">\\\
<TD WIDTH="42%"><FONT SIZE=2>Balance at January 1, 2003</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>65,979</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>196,200</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>115,539</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>\\\
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=2>24,586</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="White" VALIGN="TOP">\\\
<TD WIDTH="42%"><FONT SIZE=2>Provisions</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>527,803</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>358,173</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>244,037</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=2>338,316</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">\\\
<TD WIDTH="42%"><FONT SIZE=2>Payments</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>(480,420</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>)</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>(325,303</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>)</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>(214,381</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>)</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=2>(325,809</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>)</FONT></TD>\\\
</TR>\\\
<TR VALIGN="TOP">\\\
<TD WIDTH="42%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="White" VALIGN="TOP">\\\
<TD WIDTH="42%"><FONT SIZE=2>Balance at December 31, 2003</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>113,362</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>229,070</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>145,195</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=2>37,093</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">\\\
<TD WIDTH="42%"><FONT SIZE=2>Provisions</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>671,817</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>596,330</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>279,681</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=2>419,486</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="White" VALIGN="TOP">\\\
<TD WIDTH="42%"><FONT SIZE=2>Payments</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>(687,132</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>)</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>(452,342</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>)</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>(271,078</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>)</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=2>(412,526</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>)</FONT></TD>\\\
</TR>\\\
<TR VALIGN="TOP">\\\
<TD WIDTH="42%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">\\\
<TD WIDTH="42%"><FONT SIZE=2>Balance at December 31, 2004</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>98,047</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>373,058</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>153,798</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=2>44,053</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="White" VALIGN="TOP">\\\
<TD WIDTH="42%"><FONT SIZE=2>Provisions</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>641,189</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>663,043</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>253,499</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=2>450,901</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">\\\
<TD WIDTH="42%"><FONT SIZE=2>Payments</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>(644,460</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>)</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>(581,098</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>)</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>(273,166</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>)</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=2>(446,867</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>)</FONT></TD>\\\
</TR>\\\
<TR VALIGN="TOP">\\\
<TD WIDTH="42%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="White" VALIGN="TOP">\\\
<TD WIDTH="42%"><FONT SIZE=2>Balance at December 31, 2005</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>94,776</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>455,003</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>134,131</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>\\\
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=2>48,087</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
</TR>\\\
<TR VALIGN="TOP">\\\
<TD WIDTH="42%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE SIZE=4></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE SIZE=4></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE SIZE=4></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE SIZE=4></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
</TR>\\\
</TABLE>\\\
<!-- end of user-specified TAGGED TABLE -->\\\
\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjustments for prior years' rebate accruals have not been material. Abbott employs various techniques to verify the accuracy of claims submitted to it, and where\\\
possible, works with the organizations submitting claims to gain insight into changes that might affect the rebate amounts. For Medicaid and other government agency programs, the calculation of a\\\
rebate involves interpretations of relevant regulations, which are subject to challenge or change in interpretation. </FONT></P>\\\
\\\
<P><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income Taxes</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&#151;&nbsp;&nbsp;Abbott operates in numerous countries where its income tax returns are subject to\\\
audits and adjustments. Because Abbott operates globally, the nature of the audit items are often very complex, and the objectives of the government auditors can result in a tax on the same income in\\\
more than one country. Abbott employs internal and external tax professionals to minimize audit adjustment amounts where possible. As part of Abbott's calculation of the provision for taxes on\\\
earnings, Abbott records the amount that it expects to incur as a result of audits. Each quarter, Abbott reviews its exposures in accordance with Statement of Financial Accounting Standards (SFAS)\\\
No.&nbsp;5, "Accounting for Contingencies." In the U.S., Abbott's federal income tax returns through 2000 are settled, and the income tax returns for years after 2000 are open. Except for taxes on\\\
dividends that were remitted under the American Jobs Creation Act of 2004, Abbott does not record deferred income taxes on earnings reinvested indefinitely in foreign subsidiaries. </FONT></P>\\\
\\\
\\\
<P><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pension and Post-Employment Benefits</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&#151;&nbsp;&nbsp;Abbott offers pension benefits and\\\
post-employment health care to many of its employees. Abbott engages outside actuaries to calculate its obligations and costs under these programs. With the assistance of outside\\\
actuaries, Abbott must develop long-term assumptions, the most significant of which are the health care cost trend rate, discount rate and the expected return on plan assets. The discount\\\
rate used to measure liabilities as of December&nbsp;31, 2005 was determined based on high-quality fixed income investments that match the duration of the expected retiree benefits.\\\
Prior to December&nbsp;31, 2005, the discount rate was determined by reference to a composite corporate AA bond index. The health care cost trend rate represents Abbott's expected annual rates of\\\
change in the cost of health care benefits and is a forward projection of health care costs as of the measurement date. A difference between the assumed rates and the actual rates, which will not be\\\
known for decades, can be significant in relation to the obligations and the annual cost recorded for these programs. Recent low interest rates have significantly increased unrecognized actuarial\\\
losses for these plans. At December&nbsp;31, </FONT></P>\\\
\\\
<P ALIGN="CENTER"><FONT SIZE=2>31</FONT></P>\\\
\\\
<HR NOSHADE>\\\
<P style='page-break-before:always'></p>\\\
<!-- ZEQ.=4,SEQ=32,EFW="2167223",CP="ABBOTT LABORATORIES",DN="1",CHK=924568,FOLIO='31',FILE='DISK132:[06CHI8.06CHI1168]DS1168A.;16',USER='MBLOUNT',CD='21-FEB-2006;11:56' -->\\\
<A NAME="page_ds1168_1_32"> </A>\\\
<BR>\\\
\\\
<P><FONT SIZE=2>2005,\\\
the unrecognized actuarial losses for Abbott's defined benefit plans and medical and dental plans were $1.5&nbsp;billion and $698&nbsp;million, respectively. Unrecognized actuarial losses\\\
and gains are amortized over the remaining service periods of the employees under the corridor method, in accordance with the rules for accounting for post-employment benefits. Differences\\\
between the expected long-term return on plan assets and the actual annual return are amortized over a five-year period. Footnote 4 to the consolidated financial statements\\\
describes the impact of a one-percentage point change in the health care cost trend rate; however, there can be no certainty that a change would be limited to only one percentage point. In\\\
2005, Abbott reversed previously recorded minimum pension liability adjustments of $562&nbsp;million because the assets of certain defined benefit plans were now in excess of the accumulated benefit\\\
obligations due primarily to plan contributions in 2005. This resulted in a credit to Accumulated other comprehensive income (loss) of $346&nbsp;million, net of taxes. In 2004 and 2003, Abbott\\\
recorded minimum pension liability adjustments of $120&nbsp;million and $155&nbsp;million, respectively, because the accumulated benefit obligations for certain defined benefit plans exceeded the\\\
market value of the plans' assets. This resulted in charges to Accumulated other comprehensive income (loss) of $76&nbsp;million and $99&nbsp;million, net of taxes, in 2004 and 2003, respectively. </FONT></P>\\\
\\\
<P><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Valuation of Intangible Assets</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&#151;&nbsp;&nbsp;Abbott has acquired and continues to acquire significant intangible\\\
assets that Abbott records at fair value. Those assets which do not yet have regulatory approval and for which there are no alternative uses are expensed as acquired in-process research\\\
and development, and those that have regulatory approval are capitalized. Transactions involving the purchase or sale of intangible assets occur with some frequency between companies in the health\\\
care field, and valuations are usually based on a discounted cash flow analysis using market participant assumptions. Abbott uses a discounted cash flow model to value most of its acquired intangible\\\
assets. The discounted cash flow model requires assumptions about the timing and amount\\\
of future net cash inflows, risk, the cost of capital, and terminal values. Each of these factors can significantly affect the value of the intangible asset. Abbott engages independent valuation\\\
experts who review Abbott's critical assumptions and calculations for significant acquisitions of intangibles. Abbott reviews intangible assets for impairment each quarter using an undiscounted net\\\
cash flows approach. If the undiscounted cash flows of an intangible asset are less than the carrying value of an intangible asset, the intangible asset is written down to its fair value, which is\\\
usually the discounted cash flow amount. Where cash flows cannot be identified for an individual asset, the review is applied at the lowest group level for which cash flows are identifiable. Goodwill\\\
is reviewed for impairment annually or when an event that could result in an impairment of goodwill occurs. At December&nbsp;31, 2005 goodwill and intangibles amounted to $5.2&nbsp;billion and\\\
$4.7&nbsp;billion, respectively, and amortization expense for intangible assets amounted to approximately $490&nbsp;million in 2005. There were no impairments of goodwill in 2005, 2004 or 2003. </FONT></P>\\\
\\\
\\\
<P><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Litigation</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&#151;&nbsp;&nbsp;Abbott accounts for litigation losses in accordance with SFAS No.&nbsp;5, "Accounting\\\
for Contingencies." Under SFAS No.&nbsp;5, loss contingency provisions are recorded for probable losses at management's best estimate of a loss, or when a best estimate cannot be made, a minimum\\\
loss contingency amount is recorded. These estimates are often initially developed substantially earlier than the ultimate loss is known, and the estimates are refined each accounting period, as\\\
additional information becomes known. Accordingly, Abbott is often initially unable to develop a best estimate of loss, and therefore the minimum amount, which could be zero, is recorded. As\\\
information becomes known, either the minimum loss amount is increased, resulting in additional loss provisions, or a best estimate can be made, also resulting in additional loss provisions.\\\
Occasionally, a best estimate amount is changed to a lower amount when events result in an expectation of a more favorable outcome than previously expected. For its legal proceedings and environmental\\\
exposures, Abbott estimates the range of possible loss to be from approximately $15&nbsp;million to $60&nbsp;million. Reserves of approximately $35&nbsp;million have been recorded at\\\
December&nbsp;31, 2005 for these proceedings and exposures. These reserves represent management's best estimate of probable loss, as defined by SFAS No.&nbsp;5. </FONT></P>\\\
\\\
<P ALIGN="CENTER"><FONT SIZE=2>32</FONT></P>\\\
\\\
<HR NOSHADE>\\\
<P style='page-break-before:always'></p>\\\
<!-- ZEQ.=5,SEQ=33,EFW="2167223",CP="ABBOTT LABORATORIES",DN="1",CHK=709734,FOLIO='32',FILE='DISK132:[06CHI8.06CHI1168]DS1168A.;16',USER='MBLOUNT',CD='21-FEB-2006;11:56' -->\\\
<A NAME="page_ds1168_1_33"> </A>\\\
<BR>\\\
\\\
<P><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock Compensation</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&#151;&nbsp;&nbsp;Through December&nbsp;31, 2005, Abbott measured compensation cost using the\\\
intrinsic value-based method of accounting for stock options and replacement stock options granted to employees and disclosed the impact of the fair value method in the footnotes to the consolidated\\\
financial statements. In 2006, Abbott will adopt SFAS No.&nbsp;123 (revised 2004), "Share-Based Payment," which requires that fair value be recorded in the results of operations. Since there is no\\\
market for trading employee stock options, management must use a fair value method. There is no certainty that the results of a fair value method would be the value at which employee stock options\\\
would be traded for cash. Fair value methods require management to make several assumptions, the most significant of which are the selection of a fair value model, stock price volatility and the\\\
average life of an option. Abbott began preparing for adoption of the new standard in 2004. Abbott has readily available grant-by-grant historical activity for several years in\\\
its option administration system. Using this data, Abbott compared valuation results using the binomial method to the Black-Scholes method Abbott had been using and found the results to be comparable.\\\
Abbott evaluated whether certain holders of stock options exercised their options differently than other holders and did not find any differentiating pattern among holders. Abbott studied its implied\\\
volatility and concluded that a combination of historical and implied volatility will be a better measure than historical volatility alone. Abbott also quantified the additional paid in capital amount\\\
available for use in determining tax effects of early exercise for measurement of tax expense. Abbott will use the modified prospective method of adoption. Under this method, prior years' financial\\\
results will not include the impact of recording stock options using fair value. Footnote 10 quantifies the effect of application of fair value to 2005 and prior awards. Based upon the valuation of\\\
stock options granted in the 2006 annual grant, which comprise the majority of the grant activity for the year, Abbott estimates the impact of the 2006 change in stock compensation expense on diluted\\\
earnings per share of approximately $0.15, which includes $0.14 per diluted share for the impact of expensing the fair value of stock options. The 2006 expense for stock compensation is dependent on\\\
the number of options granted in the future, the terms of those awards and their fair value, and therefore, the effect on diluted earnings per share could change. </FONT></P>\\\
\\\
<P ALIGN="CENTER"><FONT SIZE=2>33</FONT></P>\\\
\\\
<HR NOSHADE>\\\
<P style='page-break-before:always'></p>\\\
<!-- ZEQ.=6,SEQ=34,EFW="2167223",CP="ABBOTT LABORATORIES",DN="1",CHK=902634,FOLIO='33',FILE='DISK132:[06CHI8.06CHI1168]DS1168B.;22',USER='MBLOUNT',CD='21-FEB-2006;11:56' -->\\\
<A NAME="page_ds1168_1_34"> </A>\\\
<BR>\\\
\\\
<P><FONT SIZE=2><B>Results of Operations  </B></FONT></P>\\\
\\\
<P><FONT SIZE=2><B>Sales  </B></FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table details the components of sales growth by segment for the last three years: </FONT></P>\\\
\\\
<!-- User-specified TAGGED TABLE -->\\\
<DIV ALIGN="CENTER"><TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>\\\
<TR VALIGN="BOTTOM">\\\
<TH WIDTH="53%" ALIGN="LEFT"><FONT SIZE=2>&nbsp;</FONT><BR></TH>\\\
<TH WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TH>\\\
<TH WIDTH="9%" ALIGN="LEFT"><FONT SIZE=2>&nbsp;</FONT><BR></TH>\\\
<TH WIDTH="3%" ROWSPAN=2><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>Components of Change %</B></FONT><HR NOSHADE></TH>\\\
</TR>\\\
<TR VALIGN="BOTTOM">\\\
<TH WIDTH="53%" ALIGN="LEFT"><FONT SIZE=1>&nbsp;</FONT><BR></TH>\\\
<TH WIDTH="3%" ROWSPAN=2><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH WIDTH="9%" ROWSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>Total&nbsp;%<BR>\\\
Change</B></FONT><HR NOSHADE></TH>\\\
</TR>\\\
<TR VALIGN="BOTTOM">\\\
<TH WIDTH="53%" ALIGN="LEFT"><FONT SIZE=1>&nbsp;</FONT><BR></TH>\\\
<TH WIDTH="3%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH WIDTH="6%" ALIGN="CENTER"><FONT SIZE=1><B>Price</B></FONT><HR NOSHADE></TH>\\\
<TH WIDTH="3%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH WIDTH="9%" ALIGN="CENTER"><FONT SIZE=1><B>Volume</B></FONT><HR NOSHADE></TH>\\\
<TH WIDTH="3%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH WIDTH="11%" ALIGN="CENTER"><FONT SIZE=1><B>Exchange</B></FONT><HR NOSHADE></TH>\\\
</TR>\\\
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">\\\
<TD WIDTH="53%"><FONT SIZE=2>Total Net Sales</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="6%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="11%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="White" VALIGN="TOP">\\\
<TD WIDTH="53%"><FONT SIZE=2><BR>\\\
2005 vs. 2004</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
13.5</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="6%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
0.1</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
12.1</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="11%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
1.3</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">\\\
<TD WIDTH="53%"><FONT SIZE=2>2004 vs. 2003</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>13.9</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="6%" ALIGN="RIGHT"><FONT SIZE=2>1.6</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>9.1</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="11%" ALIGN="RIGHT"><FONT SIZE=2>3.2</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="White" VALIGN="TOP">\\\
<TD WIDTH="53%"><FONT SIZE=2>2003 vs. 2002</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>13.1</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="6%" ALIGN="RIGHT"><FONT SIZE=2>1.3</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>7.8</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="11%" ALIGN="RIGHT"><FONT SIZE=2>4.0</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">\\\
<TD WIDTH="53%"><FONT SIZE=2><BR>\\\
Total U.S.</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%"><FONT SIZE=2><BR>\\\
&nbsp;</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="6%"><FONT SIZE=2><BR>\\\
&nbsp;</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%"><FONT SIZE=2><BR>\\\
&nbsp;</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="11%"><FONT SIZE=2><BR>\\\
&nbsp;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="White" VALIGN="TOP">\\\
<TD WIDTH="53%"><FONT SIZE=2><BR>\\\
2005 vs. 2004</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
13.0</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="6%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
0.8</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
12.2</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="11%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
&#151;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">\\\
<TD WIDTH="53%"><FONT SIZE=2>2004 vs. 2003</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>12.8</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="6%" ALIGN="RIGHT"><FONT SIZE=2>3.8</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>9.0</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="11%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="White" VALIGN="TOP">\\\
<TD WIDTH="53%"><FONT SIZE=2>2003 vs. 2002</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>11.6</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="6%" ALIGN="RIGHT"><FONT SIZE=2>1.6</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>10.0</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="11%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">\\\
<TD WIDTH="53%"><FONT SIZE=2><BR>\\\
Total International</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%"><FONT SIZE=2><BR>\\\
&nbsp;</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="6%"><FONT SIZE=2><BR>\\\
&nbsp;</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%"><FONT SIZE=2><BR>\\\
&nbsp;</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="11%"><FONT SIZE=2><BR>\\\
&nbsp;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="White" VALIGN="TOP">\\\
<TD WIDTH="53%"><FONT SIZE=2><BR>\\\
2005 vs. 2004</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
14.2</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="6%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
(0.7</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>)</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
12.0</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="11%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
2.9</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">\\\
<TD WIDTH="53%"><FONT SIZE=2>2004 vs. 2003</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>15.3</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="6%" ALIGN="RIGHT"><FONT SIZE=2>(1.0</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>)</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>8.9</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="11%" ALIGN="RIGHT"><FONT SIZE=2>7.4</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="White" VALIGN="TOP">\\\
<TD WIDTH="53%"><FONT SIZE=2>2003 vs. 2002</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>15.1</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="6%" ALIGN="RIGHT"><FONT SIZE=2>0.9</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>5.0</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="11%" ALIGN="RIGHT"><FONT SIZE=2>9.2</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">\\\
<TD WIDTH="53%"><FONT SIZE=2><BR>\\\
Pharmaceutical Products Segment</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%"><FONT SIZE=2><BR>\\\
&nbsp;</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="6%"><FONT SIZE=2><BR>\\\
&nbsp;</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%"><FONT SIZE=2><BR>\\\
&nbsp;</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="11%"><FONT SIZE=2><BR>\\\
&nbsp;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="White" VALIGN="TOP">\\\
<TD WIDTH="53%"><FONT SIZE=2><BR>\\\
2005 vs. 2004</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
16.1</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="6%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
1.6</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
14.5</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="11%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
&#151;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">\\\
<TD WIDTH="53%"><FONT SIZE=2>2004 vs. 2003</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>15.8</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="6%" ALIGN="RIGHT"><FONT SIZE=2>7.2</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>8.6</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="11%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="White" VALIGN="TOP">\\\
<TD WIDTH="53%"><FONT SIZE=2>2003 vs. 2002</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>19.5</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="6%" ALIGN="RIGHT"><FONT SIZE=2>3.3</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>16.2</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="11%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">\\\
<TD WIDTH="53%"><FONT SIZE=2><BR>\\\
Diagnostic Products Segment</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%"><FONT SIZE=2><BR>\\\
&nbsp;</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="6%"><FONT SIZE=2><BR>\\\
&nbsp;</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%"><FONT SIZE=2><BR>\\\
&nbsp;</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="11%"><FONT SIZE=2><BR>\\\
&nbsp;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="White" VALIGN="TOP">\\\
<TD WIDTH="53%"><FONT SIZE=2><BR>\\\
2005 vs. 2004</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
11.2</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="6%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
(0.7</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>)</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
9.9</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="11%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
2.0</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">\\\
<TD WIDTH="53%"><FONT SIZE=2>2004 vs. 2003</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>11.1</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="6%" ALIGN="RIGHT"><FONT SIZE=2>(1.2</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>)</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>6.9</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="11%" ALIGN="RIGHT"><FONT SIZE=2>5.4</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="White" VALIGN="TOP">\\\
<TD WIDTH="53%"><FONT SIZE=2>2003 vs. 2002</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>5.0</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="6%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>(1.8</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>)</FONT></TD>\\\
<TD WIDTH="11%" ALIGN="RIGHT"><FONT SIZE=2>6.8</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">\\\
<TD WIDTH="53%"><FONT SIZE=2><BR>\\\
Ross Products Segment</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%"><FONT SIZE=2><BR>\\\
&nbsp;</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="6%"><FONT SIZE=2><BR>\\\
&nbsp;</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%"><FONT SIZE=2><BR>\\\
&nbsp;</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="11%"><FONT SIZE=2><BR>\\\
&nbsp;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="White" VALIGN="TOP">\\\
<TD WIDTH="53%"><FONT SIZE=2><BR>\\\
2005 vs. 2004</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
8.5</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="6%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
(0.9</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>)</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
9.4</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="11%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
&#151;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">\\\
<TD WIDTH="53%"><FONT SIZE=2>2004 vs. 2003</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>8.9</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="6%" ALIGN="RIGHT"><FONT SIZE=2>(0.5</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>)</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>9.4</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="11%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="White" VALIGN="TOP">\\\
<TD WIDTH="53%"><FONT SIZE=2>2003 vs. 2002</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>2.3</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="6%" ALIGN="RIGHT"><FONT SIZE=2>(0.9</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>)</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>3.2</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="11%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">\\\
<TD WIDTH="53%"><FONT SIZE=2><BR>\\\
International Segment</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%"><FONT SIZE=2><BR>\\\
&nbsp;</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="6%"><FONT SIZE=2><BR>\\\
&nbsp;</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%"><FONT SIZE=2><BR>\\\
&nbsp;</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="11%"><FONT SIZE=2><BR>\\\
&nbsp;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="White" VALIGN="TOP">\\\
<TD WIDTH="53%"><FONT SIZE=2><BR>\\\
2005 vs. 2004</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
13.0</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="6%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
(0.3</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>)</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
10.4</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="11%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
2.9</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">\\\
<TD WIDTH="53%"><FONT SIZE=2>2004 vs. 2003</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>15.9</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="6%" ALIGN="RIGHT"><FONT SIZE=2>(1.0</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>)</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>9.5</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="11%" ALIGN="RIGHT"><FONT SIZE=2>7.4</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="White" VALIGN="TOP">\\\
<TD WIDTH="53%"><FONT SIZE=2>2003 vs. 2002</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>13.5</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="6%" ALIGN="RIGHT"><FONT SIZE=2>1.4</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>3.4</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="11%" ALIGN="RIGHT"><FONT SIZE=2>8.7</FONT></TD>\\\
</TR>\\\
</TABLE></DIV>\\\
<!-- end of user-specified TAGGED TABLE -->\\\
\\\
<P ALIGN="CENTER"><FONT SIZE=2>34</FONT></P>\\\
\\\
<HR NOSHADE>\\\
<P style='page-break-before:always'></p>\\\
<!-- ZEQ.=7,SEQ=35,EFW="2167223",CP="ABBOTT LABORATORIES",DN="1",CHK=387220,FOLIO='34',FILE='DISK132:[06CHI8.06CHI1168]DS1168B.;22',USER='MBLOUNT',CD='21-FEB-2006;11:56' -->\\\
<A NAME="page_ds1168_1_35"> </A>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A comparison of the product group sales by segment is as follows. Percentage changes are versus the prior year and are based on unrounded numbers. </FONT></P>\\\
\\\
<!-- User-specified TAGGED TABLE -->\\\
<DIV ALIGN="CENTER"><TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>\\\
<TR VALIGN="BOTTOM">\\\
<TH WIDTH="37%" ALIGN="LEFT"><FONT SIZE=2>&nbsp;</FONT><BR></TH>\\\
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>2005</B></FONT><HR NOSHADE></TH>\\\
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH WIDTH="9%" ALIGN="CENTER"><FONT SIZE=1><B>Percent<BR>\\\
Change</B></FONT><HR NOSHADE></TH>\\\
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>2004</B></FONT><HR NOSHADE></TH>\\\
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH WIDTH="9%" ALIGN="CENTER"><FONT SIZE=1><B>Percent<BR>\\\
Change</B></FONT><HR NOSHADE></TH>\\\
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>2003</B></FONT><HR NOSHADE></TH>\\\
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH WIDTH="9%" ALIGN="CENTER"><FONT SIZE=1><B>Percent<BR>\\\
Change</B></FONT><HR NOSHADE></TH>\\\
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
</TR>\\\
<TR VALIGN="BOTTOM">\\\
<TH WIDTH="37%" ALIGN="LEFT"><FONT SIZE=1>&nbsp;</FONT><BR></TH>\\\
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH COLSPAN=14 ALIGN="CENTER"><FONT SIZE=1><B><I>(dollars in millions)</I></B></FONT><BR>\\\
<BR></TH>\\\
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
</TR>\\\
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">\\\
<TD WIDTH="37%"><FONT SIZE=2>Pharmaceutical Products &#151;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="White" VALIGN="TOP">\\\
<TD WIDTH="37%"><FONT SIZE=2><BR>\\\
Primary Care</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2><BR>$</FONT></TD>\\\
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
4,788</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
18</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2><BR>$</FONT></TD>\\\
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
4,041</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
22</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2><BR>$</FONT></TD>\\\
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
3,324</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
26</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">\\\
<TD WIDTH="37%"><FONT SIZE=2>Specialty</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2>2,908</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>18</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2>2,460</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>28</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2>1,915</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>23</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="White" VALIGN="TOP">\\\
<TD WIDTH="37%"><FONT SIZE=2><BR>\\\
Diagnostic Products &#151;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%"><FONT SIZE=2><BR>\\\
&nbsp;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%"><FONT SIZE=2><BR>\\\
&nbsp;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%"><FONT SIZE=2><BR>\\\
&nbsp;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%"><FONT SIZE=2><BR>\\\
&nbsp;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%"><FONT SIZE=2><BR>\\\
&nbsp;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%"><FONT SIZE=2><BR>\\\
&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">\\\
<TD WIDTH="37%"><FONT SIZE=2><BR>\\\
Immunochemistry</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
2,187</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
2</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
2,141</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
2</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
2,094</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
3</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="White" VALIGN="TOP">\\\
<TD WIDTH="37%"><FONT SIZE=2>Diabetes Care</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2>1,067</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>35</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2>791</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>46</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2>542</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>10</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">\\\
<TD WIDTH="37%"><FONT SIZE=2><BR>\\\
Ross Products &#151;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%"><FONT SIZE=2><BR>\\\
&nbsp;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%"><FONT SIZE=2><BR>\\\
&nbsp;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%"><FONT SIZE=2><BR>\\\
&nbsp;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%"><FONT SIZE=2><BR>\\\
&nbsp;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%"><FONT SIZE=2><BR>\\\
&nbsp;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%"><FONT SIZE=2><BR>\\\
&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="White" VALIGN="TOP">\\\
<TD WIDTH="37%"><FONT SIZE=2><BR>\\\
Pediatric Nutritionals</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
1,097</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
(4</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2><BR>)</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
1,146</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
5</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
1,093</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
9</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">\\\
<TD WIDTH="37%"><FONT SIZE=2>Adult Nutritionals</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2>1,077</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>15</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2>934</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>15</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2>809</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>(3</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>)</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="White" VALIGN="TOP">\\\
<TD WIDTH="37%"><FONT SIZE=2><BR>\\\
International &#151;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%"><FONT SIZE=2><BR>\\\
&nbsp;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%"><FONT SIZE=2><BR>\\\
&nbsp;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%"><FONT SIZE=2><BR>\\\
&nbsp;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%"><FONT SIZE=2><BR>\\\
&nbsp;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%"><FONT SIZE=2><BR>\\\
&nbsp;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%"><FONT SIZE=2><BR>\\\
&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">\\\
<TD WIDTH="37%"><FONT SIZE=2><BR>\\\
Other Pharmaceuticals</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
3,656</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
15</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
3,184</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
21</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
2,629</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2><BR>\\\
15</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="White" VALIGN="TOP">\\\
<TD WIDTH="37%"><FONT SIZE=2>Anti-Infectives</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2>838</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>4</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2>804</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>5</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2>766</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>10</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">\\\
<TD WIDTH="37%"><FONT SIZE=2>Hospital Pharmaceuticals</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2>669</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>13</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2>592</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>15</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2>516</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>18</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="White" VALIGN="TOP">\\\
<TD WIDTH="37%"><FONT SIZE=2>Pediatric Nutritionals</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2>698</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>17</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2>595</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>13</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2>527</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>8</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">\\\
<TD WIDTH="37%"><FONT SIZE=2>Adult Nutritionals</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2>715</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>8</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2>663</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>12</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2>591</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>12</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
</TR>\\\
</TABLE></DIV>\\\
<!-- end of user-specified TAGGED TABLE -->\\\
\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sales in the Pharmaceutical Products segment of </FONT><FONT SIZE=2><I>Mobic, TriCor, Omnicef</I></FONT><FONT SIZE=2> and </FONT> <FONT SIZE=2><I>Flomax</I></FONT><FONT SIZE=2> favorably\\\
impacted Primary Care Products sales, and increased sales of </FONT><FONT SIZE=2><I>HUMIRA</I></FONT><FONT SIZE=2> favorably impacted\\\
Specialty Products sales. U.S. sales of </FONT><FONT SIZE=2><I>Synthroid</I></FONT><FONT SIZE=2>, which is now subject to generic competition, were $498&nbsp;million, $637&nbsp;million, and\\\
$565&nbsp;million in 2005, 2004 and 2003, respectively. Increased sales of </FONT><FONT SIZE=2><I>HUMIRA</I></FONT><FONT SIZE=2> and </FONT><FONT SIZE=2><I>Kaletra</I></FONT><FONT SIZE=2> also\\\
favorably impacted Other Pharmaceuticals sales in the International Segment in 2005 and 2004. Worldwide sales of </FONT><FONT SIZE=2><I>HUMIRA</I></FONT><FONT SIZE=2> totaled $1.4&nbsp;billion in\\\
2005, $852&nbsp;million in 2004 and $280&nbsp;million in 2003. Diagnostic Products and International segment products sales were favorably impacted in 2005, 2004 and 2003 by the effect of the\\\
relatively weaker U.S. dollar. Diabetes Care product sales for the Diagnostic Products segment were favorably impacted by the acquisition of TheraSense in the second quarter of 2004. In addition,\\\
Adult Nutritionals product sales for the Ross Products segment were favorably impacted by the acquisitions of ZonePerfect in the third quarter of 2003 and EAS in the fourth quarter of 2004. The\\\
decrease in sales for pediatric nutritionals in 2005 was primarily due to overall infant nutritionals non-WIC category decline and competitive share loss. Abbott\\\
has periodically sold product rights to non-strategic products and has recorded the related gains in net sales in accordance with Abbott's revenue recognition policies as discussed in\\\
footnote 1 to the consolidated financial statements. Related net sales were $177&nbsp;million in 2005, $144&nbsp;million in 2004 and $241&nbsp;million in 2003. Sales of new products in 2005 are\\\
estimated to be approximately $1.6&nbsp;billion, led by </FONT><FONT SIZE=2><I>HUMIRA</I></FONT><FONT SIZE=2> in the Pharmaceutical Products and International segments and incremental sales of\\\
approximately $260&nbsp;million from the 2004 acquisitions of TheraSense and EAS. </FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The\\\
expiration of licenses, patent protection and generic competition can affect the future revenues and operating income of Abbott. Significant ongoing generic activities, and\\\
significant patent and license expirations in the next three years are as follows. The U.S. composition of matter patent for </FONT><FONT SIZE=2><I>Depakote</I></FONT><FONT SIZE=2> expires in 2008.\\\
The Pharmaceutical Products segment's sales of </FONT><FONT SIZE=2><I>Depakote</I></FONT><FONT SIZE=2> in 2005 were $1&nbsp;billion. The Pharmaceutical Products segment has an agreement with\\\
Boehringer Ingelheim to co-promote and distribute three of its products. In 2005, Abbott and Boehringer Ingelheim amended the agreement. Effective January&nbsp;1, 2006, Abbott no longer\\\
distributes or records sales for the Boehringer Ingelheim </FONT></P>\\\
\\\
<P ALIGN="CENTER"><FONT SIZE=2>35</FONT></P>\\\
\\\
<HR NOSHADE>\\\
<P style='page-break-before:always'></p>\\\
<!-- ZEQ.=8,SEQ=36,EFW="2167223",CP="ABBOTT LABORATORIES",DN="1",CHK=1039651,FOLIO='35',FILE='DISK132:[06CHI8.06CHI1168]DS1168B.;22',USER='MBLOUNT',CD='21-FEB-2006;11:56' -->\\\
<A NAME="page_ds1168_1_36"> </A>\\\
<BR>\\\
\\\
<P><FONT SIZE=2>products,\\\
but will continue to co-promote one product, </FONT><FONT SIZE=2><I>Micardis</I></FONT><FONT SIZE=2>, through March&nbsp;31, 2006, and will receive residual commissions on\\\
Boehringer Ingelheim's sales of the three products. The amount of pretax income under the amended agreement will be the same as expected under the previous agreement. Net sales of Boehringer Ingelheim\\\
products in 2005 were approximately $2.3&nbsp;billion. In the second quarter 2004, the FDA granted approval for generic competition to </FONT><FONT SIZE=2><I>Synthroid</I></FONT><FONT SIZE=2> and\\\
generic competitors have entered the market. In 2004 and 2005, clarithromycin became subject to generic competition in several European markets. International segment sales of clarithromycin in 2005\\\
were $760&nbsp;million. In the U.S., the Pharmaceutical Products segment markets clarithromycin in two forms, the immediate release and the extended release forms, both of which are covered by\\\
additional non-composition of matter patents. In May&nbsp;2005, the composition of matter patent on clarithromycin in the U.S. expired, and several immediate release generic products\\\
were launched by competitors. Manufacturers of the extended release forms of clarithromycin were enjoined from entering the U.S. market due to Abbott's non-composition of matter patents.\\\
U.S. sales of clarithromycin in 2005 and 2004 were $306&nbsp;million and $458&nbsp;million, respectively. There may be further generic competition for clarithromycin in the U.S. and other\\\
countries in 2006 depending on the results of legal proceedings related to the patents. Upon the December&nbsp;2005 expiration of a court order related to licenses for sevoflurane, Baxter is now\\\
permitted to market a competitive form of sevoflurane. In addition, sevoflurane has been subject to generic competition from other competitors in isolated markets outside of the U.S. and further\\\
generic competition in international markets is possible. Worldwide sales of sevoflurane in 2005 were $874&nbsp;million. The composition of matter patent for </FONT> <FONT SIZE=2><I>Omnicef</I></FONT><FONT SIZE=2> expires in May&nbsp;2007. Abbott\\\
holds an additional non-composition of matter patent that expires in 2011. The Pharmaceutical\\\
Products segment sales of </FONT><FONT SIZE=2><I>Omnicef</I></FONT><FONT SIZE=2> in 2005 were $495&nbsp;million. In mid 2006, the Ross segment's co-promotion agreement for </FONT> <FONT SIZE=2><I>Synagis</I></FONT><FONT SIZE=2> will terminate. U.S.\\\
co-promotion revenues were $231&nbsp;million in 2005. Abbott will continue to market </FONT> <FONT SIZE=2><I>Synagis,</I></FONT><FONT SIZE=2> and will market its follow-on product, </FONT><FONT SIZE=2><I>Numax,</I></FONT><FONT SIZE=2> in select\\\
international markets and\\\
will receive residual commissions on U.S. sales of </FONT><FONT SIZE=2><I>Synagis</I></FONT><FONT SIZE=2>. </FONT></P>\\\
\\\
<P><FONT SIZE=2><B>Operating Earnings  </B></FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gross profit margins were 52.4&nbsp;percent of net sales in 2005, 54.9&nbsp;percent in 2004 and 55.0&nbsp;percent in 2003. The decrease in the gross profit\\\
margin in 2005 was due to unfavorable product mix, primarily as a result of increased sales of Boehringer Ingelheim products that have lower margins than other products in the Pharmaceutical Products\\\
segment. Restructuring charges, discussed below, reduced the gross profit margin in 2005 by 0.8&nbsp;percentage points. The gross profit margin in 2004 was impacted by the favorable mix effect of\\\
exchange on the gross profit margin and by unfavorable product mix, primarily increased sales of lower margin Boehringer Ingelheim products, as discussed above, in the Pharmaceutical Products segment.\\\
The gross profit margin for 2003 was impacted by a charge of $88&nbsp;million for an impairment of assets and other expenses as a result of a lower sales forecast for </FONT> <FONT SIZE=2><I>Abbokinase</I></FONT><FONT SIZE=2>; partially offset by\\\
favorable product mix, resulting mainly from increased sales in the Pharmaceutical Products segment. Gross profit\\\
margins in all years were also affected by productivity improvements, higher project expenses for new products, higher manufacturing capacity costs for anticipated unit growth, and the effects of\\\
inflation and competitive pricing pressures. </FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In\\\
the U.S., states receive price rebates from manufacturers of infant formula under the federally subsidized Special Supplemental Food Program for Women, Infants, and Children. There\\\
are also rebate programs for pharmaceutical products. These rebate programs continue to have a negative effect on the gross profit margins of the Ross and Pharmaceutical Products segments. In\\\
addition, pricing pressures unfavorably impacted the gross profit margins for the Ross Products segment in 2005, 2004 and 2003. </FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The\\\
gross profit margins for the Pharmaceutical Products segment were unfavorably impacted in 2005 and 2004 by unfavorable product mix and favorably impacted in 2003 by favorable product\\\
mix. The unfavorable product mix in 2005 and 2004 was due primarily to increased sales of lower margin Boehringer Ingelheim products and higher other manufacturing costs. The gross profit margin in\\\
2003 for the Diagnostic Products segment was impacted by the effects of a FDA consent decree. </FONT></P>\\\
\\\
<P ALIGN="CENTER"><FONT SIZE=2>36</FONT></P>\\\
\\\
<HR NOSHADE>\\\
<P style='page-break-before:always'></p>\\\
<!-- ZEQ.=9,SEQ=37,EFW="2167223",CP="ABBOTT LABORATORIES",DN="1",CHK=186934,FOLIO='36',FILE='DISK132:[06CHI8.06CHI1168]DS1168B.;22',USER='MBLOUNT',CD='21-FEB-2006;11:56' -->\\\
<A NAME="page_ds1168_1_37"> </A>\\\
<BR>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research\\\
and development expense, excluding acquired in-process research and development, was $1.8&nbsp;billion in 2005, $1.7&nbsp;billion in 2004 and $1.6&nbsp;billion\\\
in 2003 and represented increases of 7.3&nbsp;percent in 2005, 4.5&nbsp;percent in 2004 and 10.1&nbsp;percent in 2003. The majority of research and development expenditures are concentrated on\\\
pharmaceutical products. </FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Selling,\\\
general and administrative expenses increased 11.7&nbsp;percent in 2005 compared to increases of 2.4&nbsp;percent in 2004 and 29.1&nbsp;percent in 2003. The restructuring\\\
charges discussed below and an increase in a bad debt reserve associated with an unfavorable court ruling increased the percent change from 2004 by 2.7&nbsp;percentage points in 2005. In 2003,\\\
Abbott recorded in selling, general and administrative\\\
expenses, a pretax charge of $614&nbsp;million related to the settlement of the Ross enteral nutritional investigation. This 2003 charge reduced the increase in selling, general and administrative\\\
expenses by 15.0&nbsp;percentage points for 2004 and increased selling, general and administrative expenses by 16.5&nbsp;percentage points over 2002. The increases in selling, general and\\\
administrative expenses, excluding the restructuring charges and the charge for the investigation, were due primarily to increased selling and marketing support for new and existing products,\\\
including commercial activities related to sales force expansion and product launches, including Abbott's carotid stent and new </FONT><FONT SIZE=2><I>HUMIRA</I></FONT><FONT SIZE=2> indications.\\\
These increases also reflect the effects of the acquisitions of TheraSense and EAS in 2004. Increases in all three years also reflect inflation and additional selling and marketing support primarily\\\
in the Pharmaceutical Products and International segments. </FONT></P>\\\
\\\
\\\
<P><FONT SIZE=2><B>Restructurings<BR>\\\
(dollars in millions)  </B></FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In 2005, Abbott management approved plans to realign its global manufacturing operations and selected domestic and international commercial operations. In 2005,\\\
Abbott recorded pretax charges against earnings of approximately $256 reflecting the impairment of manufacturing facilities and other assets, employee severance and other related charges.\\\
Approximately $174 is classified as cost of products sold, $10 as research and development and $72 as selling, general and administrative. An additional $14 was subsequently recorded in 2005 relating\\\
to these restructurings, primarily for accelerated depreciation. As a result of product re-registration timelines required under manufacturing regulations in a number of countries,\\\
manufacturing related realignments are expected to continue into 2007. </FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The\\\
following summarizes the restructuring activity for the global pharmaceutical manufacturing operations restructuring: </FONT></P>\\\
\\\
<!-- User-specified TAGGED TABLE -->\\\
<DIV ALIGN="CENTER"><TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>\\\
<TR VALIGN="BOTTOM">\\\
<TH WIDTH="50%" ALIGN="LEFT"><FONT SIZE=2>&nbsp;</FONT><BR></TH>\\\
<TH WIDTH="3%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>Employee-<BR>\\\
Related<BR>\\\
and Other</B></FONT><HR NOSHADE></TH>\\\
<TH WIDTH="3%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>Asset<BR>\\\
Impairments</B></FONT><HR NOSHADE></TH>\\\
<TH WIDTH="3%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>Total</B></FONT><HR NOSHADE></TH>\\\
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
</TR>\\\
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">\\\
<TD WIDTH="50%"><FONT SIZE=2>2005 restructuring charges</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>$</FONT></TD>\\\
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=2>44.1</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>$</FONT></TD>\\\
<TD WIDTH="14%" ALIGN="RIGHT"><FONT SIZE=2>52.7</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>$</FONT></TD>\\\
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2>96.8</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="White" VALIGN="TOP">\\\
<TD WIDTH="50%"><FONT SIZE=2>Payments and impairments</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=2>(0.3</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>)</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="14%" ALIGN="RIGHT"><FONT SIZE=2>(52.7</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>)</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2>(53.0</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>)</FONT></TD>\\\
</TR>\\\
<TR VALIGN="TOP">\\\
<TD WIDTH="50%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">\\\
<TD WIDTH="50%"><FONT SIZE=2>Accrued balance at December 31, 2005</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>$</FONT></TD>\\\
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=2>43.8</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>$</FONT></TD>\\\
<TD WIDTH="14%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>$</FONT></TD>\\\
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2>43.8</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
</TR>\\\
<TR VALIGN="TOP">\\\
<TD WIDTH="50%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE SIZE=4></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE SIZE=4></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE SIZE=4></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
</TR>\\\
</TABLE></DIV>\\\
<!-- end of user-specified TAGGED TABLE -->\\\
\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following summarizes the restructuring activity for all other restructurings, which are individually not material: </FONT></P>\\\
\\\
<!-- User-specified TAGGED TABLE -->\\\
<DIV ALIGN="CENTER"><TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>\\\
<TR VALIGN="BOTTOM">\\\
<TH WIDTH="50%" ALIGN="LEFT"><FONT SIZE=2>&nbsp;</FONT><BR></TH>\\\
<TH WIDTH="3%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>Employee-<BR>\\\
Related<BR>\\\
and Other</B></FONT><HR NOSHADE></TH>\\\
<TH WIDTH="3%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>Asset<BR>\\\
Impairments</B></FONT><HR NOSHADE></TH>\\\
<TH WIDTH="3%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>Total</B></FONT><HR NOSHADE></TH>\\\
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
</TR>\\\
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">\\\
<TD WIDTH="50%"><FONT SIZE=2>2005 restructuring charges</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>$</FONT></TD>\\\
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=2>147.6</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>$</FONT></TD>\\\
<TD WIDTH="14%" ALIGN="RIGHT"><FONT SIZE=2>11.1</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>$</FONT></TD>\\\
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2>158.7</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="White" VALIGN="TOP">\\\
<TD WIDTH="50%"><FONT SIZE=2>Payments and impairments</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=2>(36.6</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>)</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="14%" ALIGN="RIGHT"><FONT SIZE=2>(11.1</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>)</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2>(47.7</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>)</FONT></TD>\\\
</TR>\\\
<TR VALIGN="TOP">\\\
<TD WIDTH="50%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">\\\
<TD WIDTH="50%"><FONT SIZE=2>Accrued balance at December 31, 2005</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>$</FONT></TD>\\\
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=2>111.0</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>$</FONT></TD>\\\
<TD WIDTH="14%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>$</FONT></TD>\\\
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2>111.0</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
</TR>\\\
<TR VALIGN="TOP">\\\
<TD WIDTH="50%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE SIZE=4></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE SIZE=4></TD>\\\
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE SIZE=4></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
</TR>\\\
</TABLE></DIV>\\\
<!-- end of user-specified TAGGED TABLE -->\\\
\\\
<P ALIGN="CENTER"><FONT SIZE=2>37</FONT></P>\\\
\\\
<HR NOSHADE>\\\
<P style='page-break-before:always'></p>\\\
<!-- ZEQ.=10,SEQ=38,EFW="2167223",CP="ABBOTT LABORATORIES",DN="1",CHK=223092,FOLIO='37',FILE='DISK132:[06CHI8.06CHI1168]DS1168B.;22',USER='MBLOUNT',CD='21-FEB-2006;11:56' -->\\\
<A NAME="page_ds1168_1_38"> </A>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Abbott expects to incur up to an additional $150 in future periods for restructuring plans, primarily for accelerated depreciation and plant and equipment\\\
dispositions. </FONT></P>\\\
\\\
<P><FONT SIZE=2><B>(Income) from TAP Pharmaceutical Products&nbsp;Inc. Joint Venture  </B></FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Abbott's income from the TAP Pharmaceutical Products&nbsp;Inc. joint venture was lower in 2005 and 2004 compared to 2003 due to decreased sales due to market\\\
contraction for prescription proton pump inhibitors, and in 2004 by approximately $40&nbsp;million as a result of an agreement with plaintiffs to settle litigation. </FONT></P>\\\
\\\
<P><FONT SIZE=2><B>Net Interest Expense  </B></FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net interest expense increased in 2005 and 2004 due to the impact of higher interest rates on debt levels, partially offset by higher interest income. Net\\\
interest expense decreased in 2003 due to a lower level of borrowings and lower interest rates. </FONT></P>\\\
\\\
<P><FONT SIZE=2><B>Taxes on Earnings  </B></FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The effective income tax rates on income from continuing operations were 27.0&nbsp;percent in 2005, 23.0&nbsp;percent in 2004 and 26.1&nbsp;percent in 2003.\\\
In 2005, Abbott remitted $4.3&nbsp;billion of foreign earnings in accordance with the American Jobs Creation Act of 2004 and recorded additional tax expense of $245&nbsp;million, which increased\\\
the effective tax rate by approximately 5.3&nbsp;percentage points. This was partially offset by adjustments of prior years' tax accounts resulting primarily from resolution of prior years' accrual\\\
requirements, which decreased the effective tax rate by 2.3&nbsp;percentage points. The effective tax rate for 2004 reflects adjustments of prior years' tax requirements primarily as a result of\\\
resolutions of prior years' tax audits and the effect of non-deductible acquired in-process research and development. The effect of these items for 2004 was to decrease the\\\
effective tax rate by approximately 1.2&nbsp;percentage points. The effective tax rate for 2003 includes the effect of the charge for the settlement of the Ross enteral nutritional investigation and\\\
the charges for acquired in-process research and development. The effect of these charges for 2003 was to increase the effective tax rate by approximately 2.4&nbsp;percentage points.\\\
Abbott expects to apply an annual effective rate of between 23.5&nbsp;percent and 24.0&nbsp;percent in 2006. </FONT></P>\\\
\\\
<P><FONT SIZE=2><B>Spin-off of Abbott's Core Hospital Products Business  </B></FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On April&nbsp;12, 2004, Abbott's Board of Directors declared a special dividend distribution of all of the outstanding shares of common stock of\\\
Hospira,&nbsp;Inc., payable on April&nbsp;30, 2004. Hospira included the operations relating to the manufacture and sale of hospital products including specialty injectable pharmaceuticals,\\\
medication delivery systems and critical care devices and injectable pharmaceutical\\\
contract manufacturing. Hospira included Abbott's Hospital Products segment, after that segment's reorganization on January&nbsp;1, 2004, and portions of Abbott's International segment. The income\\\
and cash flows of Hospira and the direct transaction costs of the spin-off have been presented as discontinued operations in the Consolidated Statement of Earnings and Statement of Cash\\\
Flows. Prior years' balance sheets have not been adjusted to reflect the effect of the spin-off. </FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The\\\
legal transfer of certain remaining operations and assets (net of liabilities) outside the United States is expected to occur in the first half of 2006. These operations and assets\\\
are used in the conduct of Hospira's international business and Hospira is subject to the risks and entitled to the benefits generated by these operations and assets. These assets and liabilities have\\\
been presented as held for sale in the Consolidated Balance Sheets as of December&nbsp;31, 2005 and 2004. The assets and liabilities held for sale consist primarily of inventories, trade accounts\\\
receivable, equipment and trade accounts payable, salaries and other accruals. </FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Abbott\\\
has retained liabilities for taxes on income prior to the spin-off, defined benefit, post-employment medical and dental plan obligations and assets, as of\\\
the spin-off, for most of Hospira's </FONT></P>\\\
\\\
<P ALIGN="CENTER"><FONT SIZE=2>38</FONT></P>\\\
\\\
<HR NOSHADE>\\\
<P style='page-break-before:always'></p>\\\
<!-- ZEQ.=11,SEQ=39,EFW="2167223",CP="ABBOTT LABORATORIES",DN="1",CHK=680839,FOLIO='38',FILE='DISK132:[06CHI8.06CHI1168]DS1168B.;22',USER='MBLOUNT',CD='21-FEB-2006;11:56' -->\\\
<A NAME="page_ds1168_1_39"> </A>\\\
<BR>\\\
\\\
<P><FONT SIZE=2>U.S.\\\
retired employees and U.S. retirement eligible employees and certain potential liabilities, if any, related to alleged improper pricing practices prior to the spin-off in connection\\\
with federal, state and private reimbursement for certain drugs. </FONT></P>\\\
\\\
<P><FONT SIZE=2><B>Business Combinations and Technology Acquisitions  </B></FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In 2005, Abbott acquired the remaining interest in a small medical products company that was previously accounted for under the equity method of accounting and a\\\
less than 50&nbsp;percent equity interest in a small medical products company. The aggregate cash purchase price was approximately $25&nbsp;million. Acquisition accounting resulted in the\\\
recording of non-tax deductible goodwill of approximately $69&nbsp;million, intangible assets of approximately $22&nbsp;million and a charge of approximately $17&nbsp;million for\\\
acquired in-process research and development. In 2005, Abbott acquired additional rights related to </FONT><FONT SIZE=2><I>HUMIRA</I></FONT><FONT SIZE=2> for approximately\\\
$270&nbsp;million, which will be amortized over 13&nbsp;years. </FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In\\\
2004, Abbott paid approximately $2.3&nbsp;billion for strategic business and technology acquisitions, as follows. Abbott acquired TheraSense,&nbsp;Inc., a leader in the\\\
development, manufacturing and marketing of blood glucose self-monitoring systems, for approximately $1.2&nbsp;billion in cash; i-STAT Corporation, a manufacturer of\\\
point-of-care diagnostic products for blood analysis, for approximately $394&nbsp;million in cash; EAS, a nutritional company with a portfolio of nationally recognized\\\
brands, for approximately $320&nbsp;million in cash; and\\\
Spine Next, a manufacturer of orthopedic spinal implant devices, for approximately $58&nbsp;million in cash plus additional milestone payments of up to $23&nbsp;million upon achievement of future\\\
targets. Abbott also acquired certain other product technologies for approximately $352&nbsp;million. These acquisitions resulted in a charge of $271&nbsp;million for acquired\\\
in-process research and development, intangible assets of approximately $1.3&nbsp;billion, non-tax deductible goodwill of approximately $923&nbsp;million and deferred\\\
income taxes of approximately $406&nbsp;million. Acquired intangible assets, primarily trade names, are amortized over 5 to 20&nbsp;years (average of approximately 14&nbsp;years). </FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In\\\
2003, Abbott paid approximately $459&nbsp;million for strategic business and technology acquisitions, as follows. Abbott acquired ZonePerfect Nutrition Company, a marketer of\\\
healthy and nutritious products for active people, for approximately $160&nbsp;million in cash; Integrated Vascular Systems,&nbsp;Inc., a developer of a novel vessel closure technology, for\\\
approximately $65&nbsp;million in cash; and Spinal Concepts&nbsp;Inc., a marketer of spinal fixation products used in the treatment of spinal disorders, diseases and injuries, for approximately\\\
$166&nbsp;million in cash plus additional milestone payments of up to $40&nbsp;million if agreed upon targets are met. Abbott also acquired the assets of JOMED N.V.'s coronary and peripheral\\\
interventional business for approximately $68&nbsp;million in cash. These acquisitions resulted in a charge of approximately $100&nbsp;million for acquired in-process research and\\\
development, intangible assets of approximately $222&nbsp;million and non-tax deductible goodwill of approximately $182&nbsp;million. Acquired intangible assets, primarily product\\\
technology, are amortized over 9 to 25&nbsp;years (average of approximately 16&nbsp;years). </FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Had\\\
the above acquisitions taken place on January&nbsp;1 of the previous year, consolidated sales and income would not have been significantly different from reported amounts. </FONT></P>\\\
\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In\\\
early 2006, Abbott agreed to acquire Guidant's interventional vascular and endovascular solutions businesses for $4.1&nbsp;billion in connection with Boston Scientific's acquisition\\\
of Guidant. Abbott would also pay $250&nbsp;million each upon government approvals to market Guidant's drug-eluting stent in the U.S. and in Japan. In addition, Abbott agreed to provide\\\
Boston Scientific a $900&nbsp;million 4&nbsp;percent loan and to acquire $1.4&nbsp;billion of Boston Scientific common stock directly from Boston Scientific contingent upon the closing of the\\\
Guidant acquisition. The acquisition is expected to be completed in the first half of 2006. </FONT></P>\\\
\\\
<P ALIGN="CENTER"><FONT SIZE=2>39</FONT></P>\\\
\\\
<HR NOSHADE>\\\
<P style='page-break-before:always'></p>\\\
<!-- ZEQ.=12,SEQ=40,EFW="2167223",CP="ABBOTT LABORATORIES",DN="1",CHK=514787,FOLIO='39',FILE='DISK132:[06CHI8.06CHI1168]DS1168B.;22',USER='MBLOUNT',CD='21-FEB-2006;11:56' -->\\\
<A NAME="page_ds1168_1_40"> </A>\\\
<BR>\\\
\\\
<P><FONT SIZE=2><B>Financial Condition  </B></FONT></P>\\\
\\\
<P><FONT SIZE=2><B>Cash Flow  </B></FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash from operating activities of continuing operations amounted to $5.0&nbsp;billion, $4.3&nbsp;billion and $3.4&nbsp;billion in 2005, 2004 and 2003,\\\
respectively. In 2005, 2004 and 2003, $641&nbsp;million, $482&nbsp;million and $200&nbsp;million, respectively, was contributed to the main domestic defined benefit plan. In addition, Abbott\\\
transferred approximately $45&nbsp;million to Hospira in 2004 in accordance with the employee benefit agreement governing the assumption by Hospira of certain defined benefit plan assets and\\\
liabilities. Abbott expects pension funding for its main domestic pension plan in 2006 to 2011 to be between $200&nbsp;million and $400&nbsp;million annually. The increased contribution in 2005\\\
was due, in part, to the investment of cash remitted under the American Jobs Creation Act of 2004. </FONT></P>\\\
\\\
\\\
<P><FONT SIZE=2><B>Debt and Capital  </B></FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At December&nbsp;31, 2005, Abbott's long-term debt rating was AA by Standard and Poor's and A1 by Moody's Investors Service. Abbott has readily\\\
available financial resources, including unused lines of credit of $3.0&nbsp;billion, which support domestic commercial paper borrowing arrangements. Subsequent to the announced potential\\\
acquisition of Guidant's vascular intervention and endovascular solutions businesses, Standard and Poor's affirmed their current debt ratings for Abbott and maintained their current "stable" outlook.\\\
Moody's Investors Service indicated they would likely affirm their current debt ratings for Abbott and would likely change their current outlook from "stable" to "negative." </FONT></P>\\\
\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In\\\
October&nbsp;2004, the Board of Directors authorized the purchase of 50&nbsp;million shares of Abbott's common stock from time to time and no shares were purchased under this\\\
authorization in 2004. In 2005, Abbott purchased approximately 30&nbsp;million of its common shares under this authorization at a cost of approximately $1.3&nbsp;billion. In 2004 and 2003, Abbott\\\
purchased approximately 11.7&nbsp;million and 2.7&nbsp;million, respectively, of its common shares at a cost of approximately $500&nbsp;million and $98&nbsp;million, respectively, under a\\\
prior authorization. </FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In\\\
2005, Abbott borrowed $1.9&nbsp;billion of long-term debt that matures in May&nbsp;2008 with variable interest rates above LIBOR. Proceeds from this debt were invested\\\
in short-term investments. Abbott issued $1.5&nbsp;billion of long-term debt in 2004 that matures in 2009 through 2014 with interest rates ranging from 3.5&nbsp;percent to\\\
4.35&nbsp;percent. Proceeds from this debt were used to fund the acquisition of TheraSense and to pay down domestic commercial paper borrowings. </FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Abbott\\\
retained $700&nbsp;million of proceeds from borrowings that Hospira assumed as a result of the spin-off and used these proceeds to reduce domestic commercial paper\\\
borrowings. In addition, Abbott retired long-term debt of $1.65&nbsp;billion in 2004 with proceeds from domestic commercial paper borrowings. </FONT></P>\\\
\\\
\\\
<P><FONT SIZE=2><B>Working Capital  </B></FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Working capital was $4.0&nbsp;billion at December&nbsp;31, 2005, $3.9&nbsp;billion at December&nbsp;31, 2004 and $2.7&nbsp;billion at\\\
December&nbsp;31, 2003. </FONT></P>\\\
\\\
<P><FONT SIZE=2><B>Capital Expenditures  </B></FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Capital expenditures of $1.2&nbsp;billion in 2005, $1.3&nbsp;billion in 2004 and $1.1&nbsp;billion in 2003 were principally for upgrading and expanding\\\
manufacturing, research and development, investments in information technology and administrative support facilities in all segments, and for laboratory instruments placed with customers. </FONT></P>\\\
\\\
<P ALIGN="CENTER"><FONT SIZE=2>40</FONT></P>\\\
\\\
<HR NOSHADE>\\\
<P style='page-break-before:always'></p>\\\
<!-- ZEQ.=13,SEQ=41,EFW="2167223",CP="ABBOTT LABORATORIES",DN="1",CHK=488355,FOLIO='40',FILE='DISK132:[06CHI8.06CHI1168]DS1168B.;22',USER='MBLOUNT',CD='21-FEB-2006;11:56' -->\\\
<A NAME="page_ds1168_1_41"> </A>\\\
<BR>\\\
\\\
<P><FONT SIZE=2><B>Contractual Obligations  </B></FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes Abbott's estimated contractual obligations as of December&nbsp;31, 2005. </FONT></P>\\\
\\\
<!-- User-specified TAGGED TABLE -->\\\
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>\\\
<TR VALIGN="BOTTOM">\\\
<TH COLSPAN=2 ALIGN="LEFT"><FONT SIZE=2>&nbsp;</FONT><BR></TH>\\\
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH COLSPAN=14 ALIGN="CENTER"><FONT SIZE=1><B>Payment Due By Period</B></FONT><HR NOSHADE></TH>\\\
</TR>\\\
<TR VALIGN="BOTTOM">\\\
<TH COLSPAN=2 ALIGN="LEFT"><FONT SIZE=1>&nbsp;</FONT><BR></TH>\\\
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>Total</B></FONT><HR NOSHADE></TH>\\\
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>2006</B></FONT><HR NOSHADE></TH>\\\
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>2007-2008</B></FONT><HR NOSHADE></TH>\\\
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>2009-2010</B></FONT><HR NOSHADE></TH>\\\
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>2011 and<BR>\\\
Thereafter</B></FONT><HR NOSHADE></TH>\\\
</TR>\\\
<TR VALIGN="BOTTOM">\\\
<TH COLSPAN=2 ALIGN="LEFT"><FONT SIZE=1>&nbsp;</FONT><BR></TH>\\\
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH COLSPAN=14 ALIGN="CENTER"><FONT SIZE=1><B><I>(dollars in millions)</I></B></FONT><BR>\\\
<BR></TH>\\\
</TR>\\\
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">\\\
<TD COLSPAN=2><FONT SIZE=2>Long-term debt, including current maturities and future interest payments</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>\\\
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2>7,237</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>\\\
<TD WIDTH="6%" ALIGN="RIGHT"><FONT SIZE=2>2,080</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>3,036</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>730</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>1,391</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="White" VALIGN="BOTTOM">\\\
<TD COLSPAN=2><FONT SIZE=2>Operating lease obligations</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2>348</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="6%" ALIGN="RIGHT"><FONT SIZE=2>86</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>119</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>57</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>86</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">\\\
<TD COLSPAN=2><FONT SIZE=2>Capitalized auto lease obligations</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2>106</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="6%" ALIGN="RIGHT"><FONT SIZE=2>35</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>71</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="White" VALIGN="BOTTOM">\\\
<TD COLSPAN=2><FONT SIZE=2>Purchase commitments (a)</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2>1,454</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="6%" ALIGN="RIGHT"><FONT SIZE=2>1,311</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>99</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>32</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>12</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">\\\
<TD COLSPAN=2><FONT SIZE=2>Other long-term liabilities reflected on the consolidated balance sheet &#151;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="6%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="White" VALIGN="BOTTOM">\\\
<TD WIDTH="2%"><FONT SIZE=0>&nbsp;</FONT></TD>\\\
<TD WIDTH="42%"><FONT SIZE=2>Benefit plan obligations</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2>1,275</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="6%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>208</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>217</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>850</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">\\\
<TD WIDTH="2%"><FONT SIZE=0>&nbsp;</FONT></TD>\\\
<TD WIDTH="42%"><FONT SIZE=2>Other</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2>1,305</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="6%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>393</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>208</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>704</FONT></TD>\\\
</TR>\\\
<TR VALIGN="TOP">\\\
<TD COLSPAN=2><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>\\\
</TR>\\\
<TR BGCOLOR="White" VALIGN="BOTTOM">\\\
<TD COLSPAN=2><FONT SIZE=2>Total</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>\\\
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2>11,725</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>\\\
<TD WIDTH="6%" ALIGN="RIGHT"><FONT SIZE=2>3,512</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>3,926</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>1,244</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>\\\
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>3,043</FONT></TD>\\\
</TR>\\\
<TR VALIGN="TOP">\\\
<TD COLSPAN=2><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE SIZE=4></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE SIZE=4></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE SIZE=4></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE SIZE=4></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE SIZE=4></TD>\\\
</TR>\\\
</TABLE>\\\
<!-- end of user-specified TAGGED TABLE -->\\\
\\\
<DL compact>\\\
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD><FONT SIZE=2>Purchase\\\
commitments are for purchases made in the normal course of business to meet operational and capital expenditure requirements. </FONT></DD></DL>\\\
<BR>\\\
\\\
<P><FONT SIZE=2><B>Contingent Obligations  </B></FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Abbott has periodically entered into agreements in the ordinary course of business, such as assignment of product rights, with other companies which has resulted\\\
in Abbott becoming secondarily liable for obligations that Abbott was previously primarily liable. Since Abbott no longer maintains a business relationship with the other parties, Abbott is unable to\\\
develop an estimate of the maximum potential amount of future payments, if any, under these obligations. Based upon past experience, the likelihood of payments under these agreements is remote. In\\\
addition, Abbott periodically acquires small companies in which Abbott agrees to pay contingent consideration based on attaining certain thresholds. </FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As\\\
previously noted, in connection with the potential acquisition of certain Guidant businesses, Abbott has agreed to acquire up to $6.9&nbsp;billion of assets, comprised of\\\
$4.1&nbsp;billion for the businesses, up to $500&nbsp;million in milestone payments, a $900&nbsp;million loan to Boston Scientific, and $1.4&nbsp;billion of Boston Scientific common stock. </FONT></P>\\\
\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In\\\
connection with the spin-off of Hospira, Abbott has retained liabilities for taxes on income prior to the spin-off and certain potential liabilities, if any,\\\
related to alleged improper pricing practices in connection with federal, state and private reimbursement for certain drugs. </FONT></P>\\\
\\\
<P><FONT SIZE=2><B>Recently Issued Accounting Standards  </B></FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In 2006, Abbott must adopt Statement of Financial Accounting Standards (SFAS) No.&nbsp;123 (revised 2004), "Share-Based Payment," which requires\\\
that the fair value of stock options granted to employees be recorded in the results of operations. Abbott will use the modified prospective method of adoption. Under this method, prior years'\\\
financial results will not include the impact of recording stock options using fair value. Footnote 10 quantifies the effect of application of fair value to 2005 and prior awards. Based upon the\\\
valuation of stock options granted in the 2006 annual grant, which comprise the majority of the grant activity for the year, Abbott estimates the impact of the 2006 change in stock compensation\\\
expense on diluted earnings per share of approximately $0.15, which includes $0.14 per diluted share for the impact of expensing the fair value of stock options. The 2006 expense for stock\\\
compensation is dependent on the number of options granted in the future, the terms of those awards and their fair value, and therefore, the effect on diluted earnings per share could change. </FONT></P>\\\
\\\
<P ALIGN="CENTER"><FONT SIZE=2>41</FONT></P>\\\
\\\
<HR NOSHADE>\\\
<P style='page-break-before:always'></p>\\\
<!-- ZEQ.=14,SEQ=42,EFW="2167223",CP="ABBOTT LABORATORIES",DN="1",CHK=133296,FOLIO='41',FILE='DISK132:[06CHI8.06CHI1168]DS1168B.;22',USER='MBLOUNT',CD='21-FEB-2006;11:56' -->\\\
<A NAME="page_ds1168_1_42"> </A>\\\
<BR>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In\\\
May&nbsp;2005, the Financial Accounting Standards Board (FASB) issued SFAS No.&nbsp;154, "Accounting Changes and Error Corrections." This statement generally requires\\\
retrospective application to prior periods' financial statements of voluntary changes in accounting principles. Under the prior rules, changes in accounting principles were generally recognized by\\\
including in net income of the period of the change the cumulative effect of changing to the new accounting principle. This statement does not change the previous requirements for reporting the\\\
correction of an error in previously issued financial statements, change in accounting estimate or justification of a change in accounting principle on the basis of preferability. This statement is\\\
effective for accounting changes made in fiscal years beginning after December&nbsp;15, 2005. Adoption of the provisions of the statement is not expected to have a material effect on the results of\\\
operations or financial position of Abbott. </FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In\\\
November&nbsp;2004, the FASB issued SFAS No.&nbsp;151, "Inventory Costs." This statement clarifies the accounting for the abnormal amount of idle facilities expense, freight,\\\
handling costs and wasted material. This statement requires that those items be recognized as current-period expense. In addition the statement requires that allocation of fixed overhead to the cost\\\
of conversion be based on the normal capacity of the production facilities. This statement is effective for inventory costs incurred after December&nbsp;31, 2005. Adoption of this statement will not\\\
have a material effect on the financial statements of Abbott. </FONT></P>\\\
\\\
<P><FONT SIZE=2><B>Legislative Issues  </B></FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Abbott's primary markets are highly competitive and subject to substantial government regulation. Abbott expects debate to continue in the U.S. at both the\\\
federal and the state levels over the availability, method of delivery, and payment for health care products and services. Abbott believes that if further legislation is enacted, it could have the\\\
effect of reducing access to health care products and services, or reducing prices or the rate of price increases for health care products and services. International operations are also subject to a\\\
significant degree of government regulation. It is not possible to predict the extent to which Abbott or the health care industry in general might be adversely affected by these factors in the future.\\\
A more complete discussion of these factors is contained in Item&nbsp;1, Business, and Item&nbsp;1A, Risk Factors on Form&nbsp;10-K. </FONT></P>\\\
\\\
<P><FONT SIZE=2><B>Private Securities Litigation Reform Act of 1995&nbsp;&#151; A Caution Concerning Forward-Looking<BR>\\\
Statements  </B></FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Abbott cautions investors that any forward-looking statements or\\\
projections made by Abbott, including those made in this document, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Economic,\\\
competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Exhibit&nbsp;99.1 to the Annual Report on Form&nbsp;10-K. </FONT></P>\\\
\\\
<P ALIGN="CENTER"><FONT SIZE=2>42</FONT></P>\\\
\\\
<HR NOSHADE>\\\
<P style='page-break-before:always'></p>\\\
<!-- ZEQ.=15,SEQ=43,EFW="2167223",CP="ABBOTT LABORATORIES",DN="1",CHK=952734,FOLIO='42',FILE='DISK132:[06CHI8.06CHI1168]DS1168B.;22',USER='MBLOUNT',CD='21-FEB-2006;11:56' -->\\\
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->\\\
\\\
<P><FONT SIZE=2><A\\\
NAME="page_du1168_1_43"> </A> </FONT></P>\\\
\\\
<!-- TOC_END -->\\\
\\\
<P><FONT SIZE=2><A\\\
NAME="du1168_item_7a._quantitative_and_qual__ite02669"> </A>\\\
<A NAME="toc_du1168_1"> </A>\\\
<BR></FONT><FONT SIZE=2><B>ITEM 7A.&nbsp;&nbsp;&nbsp;&nbsp;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK    <BR>    </B></FONT></P>\\\
\\\
<P ALIGN="CENTER"><FONT SIZE=2><B>Financial Instruments and Risk Management  </B></FONT></P>\\\
\\\
<P><FONT SIZE=2><B>Interest Rate Sensitive Financial Instruments  </B></FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At December&nbsp;31, 2005 and 2004, Abbott had interest rate hedge contracts totaling $3.1&nbsp;billion to manage its exposure to changes in the fair value of\\\
debt due July&nbsp;2006 through March&nbsp;2014. The effect of these hedges is to change the fixed interest rate to a variable rate. Abbott does not use derivative financial instruments, such as\\\
interest rate swaps, to manage its exposure to changes in interest rates for its investment securities. As of December&nbsp;31, 2004, Abbott had $1.6&nbsp;billion of domestic commercial paper\\\
outstanding with an average annual interest rate of 2.2% with an average remaining life of 38&nbsp;days. The fair market value of long-term debt at December&nbsp;31, 2005 and 2004\\\
amounted to $6.4&nbsp;billion and $5.0&nbsp;billion, respectively (average interest rates of 4.2% and 4.3%, respectively) with maturities through 2023. As of December&nbsp;31, 2005 and 2004, the\\\
fair market value of current and long-term investment securities amounted to $80&nbsp;million and $854&nbsp;million, respectively. A hypothetical 100-basis point change in\\\
the interest rates would not have a material effect on cash flows, income or market values. (A 100-basis point change is believed to be a reasonably possible near-term change\\\
in rates.) </FONT></P>\\\
\\\
<P><FONT SIZE=2><B>Market Price Sensitive Financial Instruments  </B></FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Abbott maintains a portfolio of available-for-sale equity securities from strategic technology acquisitions. The market value of these\\\
investments was approximately $99&nbsp;million and $96&nbsp;million, respectively, as of December&nbsp;31, 2005 and 2004. Abbott monitors these investments for other than temporary declines in\\\
market value, and charges impairment losses to income when an other\\\
than temporary decline in value occurs. A hypothetical 20&nbsp;percent decrease in the share prices of these investments would decrease their fair value at December&nbsp;31, 2005 by approximately\\\
$20&nbsp;million. (A 20&nbsp;percent decrease is believed to be a reasonably possible near-term change in share prices.) </FONT></P>\\\
\\\
<P><FONT SIZE=2><B>Non-Publicly Traded Equity Securities  </B></FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Abbott maintains a portfolio of equity securities from strategic technology acquisitions that are not traded on public stock exchanges. The carrying value of\\\
these investments was approximately $17&nbsp;million and $30&nbsp;million, respectively, as of December&nbsp;31, 2005 and 2004. No individual investment is in excess of $9&nbsp;million. Abbott\\\
monitors these investments for other than temporary declines in market value, and charges impairment losses to income when an other than temporary decline in estimated value occurs. </FONT></P>\\\
\\\
<P><FONT SIZE=2><B>Foreign Currency Sensitive Financial Instruments  </B></FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Abbott enters into foreign currency forward exchange contracts to manage its exposure to foreign currency denominated intercompany loans and trade payables and\\\
third-party trade payables and receivables. The contracts are marked-to-market, and resulting gains or losses are reflected in income and are generally offset by losses or\\\
gains on the foreign currency exposure being managed. At December&nbsp;31, 2005 and 2004, Abbott held $3.9&nbsp;billion and $3.3&nbsp;billion, respectively, of such contracts, which all mature\\\
in the following calendar year. </FONT></P>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In\\\
addition, certain Abbott foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates for anticipated\\\
intercompany purchases by those subsidiaries whose functional currencies are not the U.S. dollar. These contracts are designated as cash flow hedges of the variability of the cash flows due to changes\\\
in foreign exchange rates and are marked-to-market with the resulting gains or losses reflected in Accumulated other comprehensive income (loss). Gains or losses will be\\\
included in Cost of products sold at the time the products are sold, generally within the next calendar year. At December&nbsp;31, 2005 and 2004, Abbott held $222&nbsp;million and\\\
$984&nbsp;million, respectively, of such contracts, which all mature in the following calendar year. </FONT></P>\\\
\\\
<P ALIGN="CENTER"><FONT SIZE=2>43</FONT></P>\\\
\\\
<HR NOSHADE>\\\
<P style='page-break-before:always'></p>\\\
<!-- ZEQ.=1,SEQ=44,EFW="2167223",CP="ABBOTT LABORATORIES",DN="1",CHK=559226,FOLIO='43',FILE='DISK132:[06CHI8.06CHI1168]DU1168A.;9',USER='MBLOUNT',CD='21-FEB-2006;11:54' -->\\\
<A NAME="page_du1168_1_44"> </A>\\\
<BR>\\\
\\\
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The\\\
following table reflects the total foreign currency forward contracts outstanding at December&nbsp;31, 2005 and 2004: </FONT></P>\\\
\\\
<!-- User-specified TAGGED TABLE -->\\\
<DIV ALIGN="CENTER"><TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>\\\
<TR VALIGN="BOTTOM">\\\
<TH WIDTH="25%" ALIGN="LEFT"><FONT SIZE=2>&nbsp;</FONT><BR></TH>\\\
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH COLSPAN=7 ALIGN="CENTER"><FONT SIZE=1><B>2005</B></FONT><HR NOSHADE></TH>\\\
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH COLSPAN=7 ALIGN="CENTER"><FONT SIZE=1><B>2004</B></FONT><HR NOSHADE></TH>\\\
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
</TR>\\\
<TR VALIGN="BOTTOM">\\\
<TH WIDTH="25%" ALIGN="LEFT"><FONT SIZE=1>&nbsp;</FONT><BR></TH>\\\
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>Contract<BR>\\\
Amount</B></FONT><HR NOSHADE></TH>\\\
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH WIDTH="10%" ALIGN="CENTER"><FONT SIZE=1><B>Average<BR>\\\
Exchange<BR>\\\
Rate</B></FONT><HR NOSHADE></TH>\\\
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>Fair and<BR>\\\
Carrying<BR>\\\
Value<BR>\\\
Receivable/<BR>\\\
(Payable)</B></FONT><HR NOSHADE></TH>\\\
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>Contract<BR>\\\
Amount</B></FONT><HR NOSHADE></TH>\\\
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH WIDTH="10%" ALIGN="CENTER"><FONT SIZE=1><B>Average<BR>\\\
Exchange<BR>\\\
Rate</B></FONT><HR NOSHADE></TH>\\\
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>Fair and<BR>\\\
Carrying<BR>\\\
Value<BR>\\\
Receivable/<BR>\\\
(Payable)</B></FONT><HR NOSHADE></TH>\\\
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
</TR>\\\
<TR VALIGN="BOTTOM">\\\
<TH WIDTH="25%" ALIGN="LEFT"><FONT SIZE=1>&nbsp;</FONT><BR></TH>\\\
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
<TH COLSPAN=15 ALIGN="CENTER"><FONT SIZE=1><B><I>(dollars in millions)</I></B></FONT><BR>\\\
<BR></TH>\\\
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>\\\
</TR>\\\
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">\\\
<TD WIDTH="25%"><FONT SIZE=1><B>Receive primarily U.S. Dollars<BR>\\\
in exchange for<BR>\\\
the following currencies:</B></FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="10%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="11%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="10%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="11%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="White" VALIGN="BOTTOM">\\\
<TD WIDTH="25%"><FONT SIZE=2>Euro</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>1,519</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2>1.184</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>\\\
<TD WIDTH="11%" ALIGN="RIGHT"><FONT SIZE=2>(1.4</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>)</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>1,688</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2>1.284</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>\\\
<TD WIDTH="11%" ALIGN="RIGHT"><FONT SIZE=2>(39.1</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>)</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">\\\
<TD WIDTH="25%"><FONT SIZE=2>British Pound</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>1,148</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2>1.738</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="11%" ALIGN="RIGHT"><FONT SIZE=2>7.2</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>1,112</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2>1.845</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="11%" ALIGN="RIGHT"><FONT SIZE=2>(26.7</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>)</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="White" VALIGN="BOTTOM">\\\
<TD WIDTH="25%"><FONT SIZE=2>Japanese Yen</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>513</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2>113.4</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="11%" ALIGN="RIGHT"><FONT SIZE=2>(18.4</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>)</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>533</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2>107.3</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="11%" ALIGN="RIGHT"><FONT SIZE=2>9.2</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">\\\
<TD WIDTH="25%"><FONT SIZE=2>Canadian Dollar</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>425</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2>1.176</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="11%" ALIGN="RIGHT"><FONT SIZE=2>(2.1</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>)</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>301</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2>1.274</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="11%" ALIGN="RIGHT"><FONT SIZE=2>(20.0</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>)</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="White" VALIGN="BOTTOM">\\\
<TD WIDTH="25%"><FONT SIZE=2>All other currencies</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>487</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2>N/A</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="11%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>601</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2>N/A</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="11%" ALIGN="RIGHT"><FONT SIZE=2>(3.3</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>)</FONT></TD>\\\
</TR>\\\
<TR VALIGN="TOP">\\\
<TD WIDTH="25%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
</TR>\\\
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">\\\
<TD WIDTH="25%"><FONT SIZE=2>Total</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>4,092</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>\\\
<TD WIDTH="11%" ALIGN="RIGHT"><FONT SIZE=2>(14.7</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>)</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>\\\
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>4,235</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>\\\
<TD WIDTH="11%" ALIGN="RIGHT"><FONT SIZE=2>(79.9</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>)</FONT></TD>\\\
</TR>\\\
<TR VALIGN="TOP">\\\
<TD WIDTH="25%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE SIZE=4></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE SIZE=4></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE SIZE=4></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE SIZE=4></TD>\\\
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>\\\
</TR>\\\
</TABLE></DIV>\\\
<!-- end of user-specified TAGGED TABLE -->\\\
\\\
<P ALIGN="CENTER"><FONT SIZE=2>44</FONT></P>\\\
\\\
<HR NOSHADE>\\\
<P style='page-break-before:always'></p>\\\
<!-- ZEQ.=2,SEQ=45,EFW="2167223",CP="ABBOTT LABORATORIES",DN="1",CHK=602804,FOLIO='44',FILE='DISK132:[06CHI8.06CHI1168]DU1168A.;9',USER='MBLOUNT',CD='21-FEB-2006;11:54' -->\\\
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->\\\
\\\
<P><FONT SIZE=2><A\\\
NAME="page_fa1168_1_45"> </A> </FONT></P>\\\
\\\
<!-- TOC_END -->\\\
\\\
<!-- SEQ=,FILE='QUICKLINK',USER=MWEINST,SEQ=,EFW="2167223",CP="ABBOTT LABORATORIES",DN="1" -->\\\
<!-- TOCEXISTFLAG -->\\\
</BODY>\\\
</HTML>\\\
</TEXT>\\\
\\\
\}}